m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00341)

Target Name	Myc proto-oncogene protein (MYC)
Synonyms	Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64; BHLHE39 Click to Show/Hide
Gene Name	MYC
Chromosomal Location	8q24.21
Function	Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells (By similarity). Functions with TAF6L to activate target gene expression through RNA polymerase II pause release (By similarity). Positively regulates transcription of HNRNPA1, HNRNPA2 and PTBP1 which in turn regulate splicing of pyruvate kinase PKM by binding repressively to sequences flanking PKM exon 9, inhibiting exon 9 inclusion and resulting in exon 10 inclusion and production of the PKM M2 isoform. Click to Show/Hide
Gene ID	4609
Uniprot ID	MYC_HUMAN
HGNC ID	HGNC:7553
Ensembl Gene ID	ENSG00000136997
KEGG ID	hsa:4609

Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)

MYC can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).

Browse Regulator

Browse Disease

Browse Drug

Methyltransferase-like 3 (METTL3) [WRITER]

Regulator Info

*Representative RNA-seq result indicating the expression of this target gene regulated by METTL3*
Cell Line	LNCaP cell line	Homo sapiens
Treatment: shMETTL3 LNCaP cells Control: shControl LNCaP cells		GSE147884
Regulation		logFC: -6.39E-01 p-value: 4.30E-103
More Results	Click to View More RNA-seq Results
*Representative RIP-seq result supporting the interaction between MYC and the regulator*
Cell Line	MDA-MB-231	Homo sapiens
Regulation	logFC: 1.10E+00	GSE60213

In total 12 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene				[1]
Response Summary	METTL3 depletion in human myeloid leukemia cell lines induces cell differentiation and apoptosis and delays leukemia progression in recipient mice in vivo. Single-nucleotide-resolution mapping of m6A coupled with ribosome profiling reveals that m6A promotes the translation of Myc proto-oncogene protein (MYC), BCL2 and PTEN mRNAs in the human acute myeloid leukemia MOLM-13 cell line. Moreover, loss of METTL3 leads to increased levels of phosphorylated AKT.
Target Regulation	Up regulation
Responsed Disease	Acute myeloid leukaemia		ICD-11: 2A60	Disease Info
Cell Process	Cell differentiation and apoptosis
Cell Process	Apoptosis (hsa04210)
In-vitro Model	HSPC (Human hematopoietic stem cell)
In-vivo Model	500,000 selected cells were injected via tail vein or retro-orbital route into female NSG (6-8 week old) recipient mice that had been sublethally irradiated with 475 cGy one day before transplantation.
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene				[2]
Response Summary	METTL3 level was slightly increased in AML-M5 patients,and its expression was significantly higher in immature cells than in mature monocytes.METTL3 acts as an oncogene in MOLM13 cells by upregulating Myc proto-oncogene protein (MYC) expression.
Target Regulation	Up regulation
Responsed Disease	Acute myeloid leukaemia		ICD-11: 2A60	Disease Info
Cell Process	Cell proliferation
In-vitro Model	MOLM-13	Adult acute myeloid leukemia	Homo sapiens	CVCL_2119
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene				[3]
Response Summary	In oral squamous cell carcinoma, YTH N6-methyladenosine RNA binding protein 1 (YTH domain family, member 1 [YTHDF1]) mediated the m6A-increased stability of Myc proto-oncogene protein (MYC) mRNA catalyzed by METTL3.
Target Regulation	Up regulation
Responsed Disease	Oral squamous cell carcinoma		ICD-11: 2B6E.0	Disease Info
Pathway Response	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	CAL-27	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1107
	NHOK (Normal oral keratinocytes)
	SCC-15	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1681
	SCC-25	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1682
	TSCCa	Endocervical adenocarcinoma	Homo sapiens	CVCL_VL15
In-vivo Model	The stable transfection of SCC25 cells (1 × 10⁷ cells in 0.1 mL) with lenti-sh-METTL3 or blank vectors was injected subcutaneously into BALB/c nude mice.
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene				[4]
Response Summary	In gastric cancer, several component molecules (e.g., MCM5, MCM6, etc.) of Myc proto-oncogene protein (MYC) target genes were mediated by METTL3 via altered m6A modification.
Target Regulation	Up regulation
Responsed Disease	Gastric cancer		ICD-11: 2B72	Disease Info
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
In-vitro Model	GES-1	Normal	Homo sapiens	CVCL_EQ22
	HGC-27	Gastric carcinoma	Homo sapiens	CVCL_1279
	MGC-803	Gastric mucinous adenocarcinoma	Homo sapiens	CVCL_5334
	MKN45	Gastric adenocarcinoma	Homo sapiens	CVCL_0434
	MKN74	Gastric tubular adenocarcinoma	Homo sapiens	CVCL_2791
	pGCC (Primary GC cells)
	SGC-7901	Gastric carcinoma	Homo sapiens	CVCL_0520
In-vivo Model	A total of 2 × 10⁶ GC cells were injected into the flank of nude mice in a 1:1 suspension of BD Matrigel (BD Biosciences) in phosphate-buffered saline (PBS) solution.
Experiment 5 Reporting the m6A Methylation Regulator of This Target Gene				[5]
Response Summary	METTL3 enhanced Myc proto-oncogene protein (MYC) m6A methylation and increased MYC translation, which could potentiate the proliferation, migration and invasion of gastric cancer cells.
Target Regulation	Up regulation
Responsed Disease	Gastric cancer		ICD-11: 2B72	Disease Info
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
	Cell apoptosis
In-vitro Model	AGS	Gastric adenocarcinoma	Homo sapiens	CVCL_0139
	AZ-521	Duodenal adenocarcinoma	Homo sapiens	CVCL_2862
	GES-1	Normal	Homo sapiens	CVCL_EQ22
	MKN45	Gastric adenocarcinoma	Homo sapiens	CVCL_0434
	SGC-7901	Gastric carcinoma	Homo sapiens	CVCL_0520
In-vivo Model	The GC cell line MKN-45 stably infected with lentivirus expressing sh-HBXIP was prepared into 5 × 10⁷ cells/mL cell suspension.
Experiment 6 Reporting the m6A Methylation Regulator of This Target Gene				[5]
Response Summary	Expressions of HBXIP, METTL3 and Myc proto-oncogene protein (MYC) were all determined to be upregulated in both GC tissues and cells. HBXIP plays an oncogenic role in GC via METTL3-mediated MYC mRNA m6A modification.
Target Regulation	Up regulation
Responsed Disease	Gastric cancer		ICD-11: 2B72	Disease Info
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
	Cell apoptosis
In-vitro Model	SGC-7901	Gastric carcinoma	Homo sapiens	CVCL_0520
	MKN45	Gastric adenocarcinoma	Homo sapiens	CVCL_0434
	GES-1	Normal	Homo sapiens	CVCL_EQ22
	AZ-521	Duodenal adenocarcinoma	Homo sapiens	CVCL_2862
	AGS	Gastric adenocarcinoma	Homo sapiens	CVCL_0139
In-vivo Model	The GC cell line MKN-45 stably infected with lentivirus expressing sh-HBXIP was prepared into 5 × 10⁷ cells/mL cell suspension. The cell suspension was injected into the left axilla of nude mice using a 1 mL syringe as the sh-HBXIP group (n = 6). The GC cell line MKN-45 infected with the lentivirus expressing sh-NC was dispersed into the cell suspension, which was injected into nude mice as the sh-NC group (n = 6). Tumor growth was observed and data were recorded after inoculation. On the 26th day, all nude mice were euthanized by cervical dislocation and the tumors were resected and weighed.
Experiment 7 Reporting the m6A Methylation Regulator of This Target Gene				[6]
Response Summary	METTL3 exerted its function through enhancing Myc proto-oncogene protein (MYC) expression, at least partially in an m6A-IGF2BP1-dependent manner. Knockdown of METTL3 suppressed colorectal cancer cell proliferation in vitro and in vivo.
Target Regulation	Up regulation
Responsed Disease	Colorectal cancer		ICD-11: 2B91	Disease Info
Cell Process	Cell proliferation
In-vitro Model	HEK293T	Normal	Homo sapiens	CVCL_0063
	Caco-2	Colon adenocarcinoma	Homo sapiens	CVCL_0025
	HCT 116	Colon carcinoma	Homo sapiens	CVCL_0291
	HT29	Colon cancer	Mus musculus	CVCL_A8EZ
	LoVo	Colon adenocarcinoma	Homo sapiens	CVCL_0399
	SW480	Colon adenocarcinoma	Homo sapiens	CVCL_0546
	SW620	Colon adenocarcinoma	Homo sapiens	CVCL_0547
In-vivo Model	METTL3 stable knockdown or overexpression HCT116 cells were collected and resuspended at a density of 5 × 10⁶ or 3 × 10⁶ cells per 150 uL PBS.
Experiment 8 Reporting the m6A Methylation Regulator of This Target Gene				[7]
Response Summary	LCAT3 upregulation is attributable to N6-methyladenosine (m6A) modification mediated by methyltransferase like 3 (METTL3), leading to LCAT3 stabilization. LCAT3 as a novel oncogenic lncRNA in the lung, and validated the LCAT3-FUBP1-Myc proto-oncogene protein (MYC) axis as a potential therapeutic target for lung adenocarcinomas.
Target Regulation	Up regulation
Responsed Disease	Lung adenocarcinoma		ICD-11: 2C25.0	Disease Info
In-vitro Model	A-549	Lung adenocarcinoma	Homo sapiens	CVCL_0023
	Calu-1	Lung squamous cell carcinoma	Homo sapiens	CVCL_0608
	HEK293T	Normal	Homo sapiens	CVCL_0063
	HOP-62	Lung adenocarcinoma	Homo sapiens	CVCL_1285
In-vivo Model	For the in vivo tumorigenicity assay, female BALB/c nude mice (ages 4-5 weeks) were randomly divided into two groups (n = 6/group). Calu1 cells (4 × 10⁶) that had been stably transfected with sh-LCAT3 or scramble were implanted subcutaneously into the nude mice. Tumor growth was measured after one week, and tumor volumes were calculated with the following formula: Volume (cm³) = (length × width²)/2. After four weeks, the mice were euthanized, and the tumors were collected and weighed. For the in vivo tumor invasion assay, 1.2 × 10⁶ scramble or shLCAT3 cells were injected intravenously into the tail vein of nude mice (n = 6/group). 1.5 mg luciferin (Gold Biotech, St Louis, MO, USA) was administered once a week for 4 weeks, to monitor metastases using an IVIS@ Lumina II system (Caliper Life Sciences, Hopkinton, MA, USA).
Experiment 9 Reporting the m6A Methylation Regulator of This Target Gene				[8]
Response Summary	This study revealed that m6A methylation is closely related to the poor prognosis of non-small cell lung cancer patients via interference with the TIME, which suggests that m6A plays a role in optimizing individualized immunotherapy management and improving prognosis. The expression levels of METTL3, FTO and YTHDF1 in non-small cell lung cancer were changed. Patients in Cluster 1 had lower immunoscores, higher programmed death-ligand 1 (PD-L1) expression, and shorter overall survival compared to patients in Cluster 2. The Myc proto-oncogene protein (MYC) targets, E2 transcription Factor (E2F) targets were significantly enriched.
Responsed Disease	Non-small-cell lung carcinoma		ICD-11: 2C25.Y	Disease Info
Pathway Response	p53 signaling pathway			hsa04115
	Central carbon metabolism in cancer			hsa05230
	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Experiment 10 Reporting the m6A Methylation Regulator of This Target Gene				[9]
Response Summary	METTL3 enhanced Myc proto-oncogene protein (MYC) expression by increasing m6A levels of MYC mRNA transcript, leading to oncogenic functions in prostate cancer.
Target Regulation	Up regulation
Responsed Disease	Prostate cancer		ICD-11: 2C82	Disease Info
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
In-vitro Model	LNCaP C4-2	Prostate carcinoma	Homo sapiens	CVCL_4782
	DU145	Prostate carcinoma	Homo sapiens	CVCL_0105
	LNCaP	Prostate carcinoma	Homo sapiens	CVCL_0395
	PC-3	Prostate carcinoma	Homo sapiens	CVCL_0035
Experiment 11 Reporting the m6A Methylation Regulator of This Target Gene				[10]
Response Summary	AF4/FMR2 family member 4 (AFF4), two key regulators of NF-Kappa-B pathway (IKBKB and RELA) and Myc proto-oncogene protein (MYC) were further identified as direct targets of METTL3-mediated m6A modification.overexpression of METTL3 significantly promoted Bladder cancer cell growth and invasion.
Target Regulation	Up regulation
Responsed Disease	Bladder cancer		ICD-11: 2C94	Disease Info
Cell Process	Glucose metabolism
Experiment 12 Reporting the m6A Methylation Regulator of This Target Gene				[11]
Response Summary	Mettl3 activates the cyst-promoting c-Myc and cAMP pathways through enhanced Myc proto-oncogene protein (MYC) and Avpr2 mRNA m6A modification and translation. Thus, Mettl3 promotes Autosomal dominant polycystic kidney disease and links methionine utilization to epitranscriptomic activation of proliferation and cyst growth.
Target Regulation	Up regulation
Responsed Disease	Polycystic kidney disease		ICD-11: GB81	Disease Info
In-vitro Model	mIMCD-3	Normal	Mus musculus	CVCL_0429
In-vivo Model	The clone, with one wild-type Mettl3 allele and one L1L2_Bact_P cassette inserted allele, was injected into C57BL/6 blastocysts. Mettl3-targeted mouse line was established from a germline-transmitting chimera. The chimeric mouse was crossed to C57BL/6 Flp mice to excise the neomycin resistance system.

YTH domain-containing family protein 1 (YTHDF1) [READER]

Regulator Info

*Representative RNA-seq result indicating the expression of this target gene regulated by YTHDF1*
Cell Line	Embryonic stem cells	Mus musculus
Treatment: YTHDF1-/- mESCs Control: Wild type ESCs		GSE147849
Regulation		logFC: -1.55E+00 p-value: 2.76E-03
More Results	Click to View More RNA-seq Results
*Representative RIP-seq result supporting the interaction between MYC and the regulator*
Cell Line	Hela	Homo sapiens
Regulation	logFC: 1.21E+00	GSE63591

In total 2 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene				[3]
Response Summary	In oral squamous cell carcinoma, YTH N6-methyladenosine RNA binding protein 1 (YTH domain family, member 1 [YTHDF1]) mediated the m6A-increased stability of Myc proto-oncogene protein (MYC) mRNA catalyzed by METTL3.
Target Regulation	Up regulation
Responsed Disease	Oral squamous cell carcinoma		ICD-11: 2B6E.0	Disease Info
Pathway Response	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	CAL-27	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1107
	NHOK (Normal oral keratinocytes)
	SCC-15	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1681
	SCC-25	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1682
	TSCCa	Endocervical adenocarcinoma	Homo sapiens	CVCL_VL15
In-vivo Model	The stable transfection of SCC25 cells (1 × 10⁷ cells in 0.1 mL) with lenti-sh-METTL3 or blank vectors was injected subcutaneously into BALB/c nude mice.
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene				[8]
Response Summary	This study revealed that m6A methylation is closely related to the poor prognosis of non-small cell lung cancer patients via interference with the TIME, which suggests that m6A plays a role in optimizing individualized immunotherapy management and improving prognosis. The expression levels of METTL3, FTO and YTHDF1 in non-small cell lung cancer were changed. Patients in Cluster 1 had lower immunoscores, higher programmed death-ligand 1 (PD-L1) expression, and shorter overall survival compared to patients in Cluster 2. The Myc proto-oncogene protein (MYC) targets, E2 transcription Factor (E2F) targets were significantly enriched.
Responsed Disease	Non-small-cell lung carcinoma		ICD-11: 2C25.Y	Disease Info
Pathway Response	p53 signaling pathway			hsa04115
	Central carbon metabolism in cancer			hsa05230
	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235

YTH domain-containing family protein 2 (YTHDF2) [READER]

Regulator Info

*Representative RNA-seq result indicating the expression of this target gene regulated by YTHDF2*
Cell Line	GSC11 cell line	Homo sapiens
Treatment: siYTHDF2 GSC11 cells Control: siControl GSC11 cells		GSE142825
Regulation		logFC: 8.94E-01 p-value: 8.57E-07
More Results	Click to View More RNA-seq Results
*Representative RIP-seq result supporting the interaction between MYC and the regulator*
Cell Line	Hela	Homo sapiens
Regulation	logFC: 1.40E+00	GSE49339

In total 3 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene				[12]
Response Summary	The IGF1/IGF1R inhibitor, linsitinib for further investigation based upon the role of the IGF pathway member, IGFBP3, as a downstream effector of YTHDF2-Myc proto-oncogene protein (MYC) axis in GSCs. Inhibiting glioblastoma stem cells viability without affecting NSCs and impairing in vivo glioblastoma growth.
Target Regulation	Up regulation
Responsed Disease	Glioblastoma		ICD-11: 2A00.00	Disease Info
Responsed Drug	Linsitinib		Phase 3	Drug Info
In-vitro Model	NSC11 (Pluripotent derived neural progenitor cell)
	NHA (Normal human astrocytes)
	HNP1 (A human neural progenitor cell)
	ENSA (A human embryonic stem derived neural progenitor cell)
In-vivo Model	Implanting 5000 human derived GSCs into the right cerebral cortex of NSG mice at a depth of 3.5 mm under a University of California, San Diego Institutional Animal Care and Use Committee (IACUC) approved protocol. Brains were harvested and fixed in 4% formaldehyde, cryopreserved in 30% sucrose, and then cryosectioned. Hematoxylin and eosin (H&E) staining was performed on sections for histological analysis. In parallel survival experiments, mice were observed until the development of neurological signs. For in vivo drug treatment studies, intracranial xenografts were generated by implanting 5000 patient-derived GSCs (387 and 4121) into the right cerebral cortex of NSG mice as described above. Mice recovered for 7 days were randomly assigned into drug vs. treatment group by a blinded investigator. Mice were then treated daily with either vehicle (25 mM Tartaric acid) or 50 mg/kg linsitinib by oral gavage.
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene				[12]
Response Summary	The m6A reader YTHDF2 stabilized Myc proto-oncogene protein (MYC) mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivo glioblastoma growth. YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2-MYC-IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.
Target Regulation	Up regulation
Responsed Disease	Glioma		ICD-11: 2A00.0	Disease Info
Pathway Response	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	()
	HNP1 (A human neural progenitor cell)
	NHA (Normal human astrocytes)
	NSC11 (Pluripotent derived neural progenitor cell)
In-vivo Model	For in vivo drug treatment studies, intracranial xenografts were generated by implanting 5000 patient-derived GSCs (387 and 4121) into the right cerebral cortex of NSG mice as described above.
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene				[13]
Response Summary	LCAT3 upregulation is attributable to m6A modification mediated by METTL3, leading to LCAT3 stabilization. Treated cells with tamoxifen to induce MYC activity. Highlights the therapeutic potential of RBPs by uncovering a critical role for YTHDF2 in counteracting the global increase of mRNA synthesis in Myc proto-oncogene protein (MYC)-driven breast cancers.
Responsed Disease	Breast cancer		ICD-11: 2C60	Disease Info
Responsed Drug	Tamoxifen		Approved	Drug Info
Pathway Response	MAPK signaling pathway			hsa04010
Cell Process	Epithelial-to-mesenchymal transition
	Cell apoptosis
In-vitro Model	HEK293T	Normal	Homo sapiens	CVCL_0063
	MCF-7	Invasive breast carcinoma	Homo sapiens	CVCL_0031
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens	CVCL_0062
	MBA-MD-231 (Human breast cancer cell)
	MYC-ER HMEC (Human mammary epithelial cells expressing a MYC estrogen receptor fusion)
	SK-BR-3	Breast adenocarcinoma	Homo sapiens	CVCL_0033
In-vivo Model	To induce recombination at 8 weeks of age both CAG-CreERT;Ythdf2^fl/fl and Ythdf2^fl/fl littermates were injected with 75mg/kg body weight tamoxifen dissolved in corn oil daily for 5 days.

Fat mass and obesity-associated protein (FTO) [ERASER]

Regulator Info

*Representative RNA-seq result indicating the expression of this target gene regulated by FTO*
Cell Line	NB4 cell line	Homo sapiens
Treatment: shFTO NB4 cells Control: shNS NB4 cells		GSE103494
Regulation		logFC: -6.81E-01 p-value: 3.45E-03
More Results	Click to View More RNA-seq Results

In total 8 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene				[14]
Response Summary	This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/Myc proto-oncogene protein (MYC)/CEBPA signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling.
Target Regulation	Down regulation
Responsed Disease	Glioma		ICD-11: 2A00.0	Disease Info
Responsed Drug	R-2HG		Investigative	Drug Info
Cell Process	Glutamine metabolism
Cell Process	Cell apoptosis
In-vitro Model	8-MG-BA	Glioblastoma	Homo sapiens	CVCL_1052
	A-172	Glioblastoma	Homo sapiens	CVCL_0131
	DK-MG	Glioblastoma	Homo sapiens	CVCL_1173
	GaMG	Glioblastoma	Homo sapiens	CVCL_1226
	HEL	Erythroleukemia	Homo sapiens	CVCL_0001
	Jurkat	T acute lymphoblastic leukemia	Homo sapiens	CVCL_0065
	KOCL-45	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3993
	KOCL-48	Childhood acute monocytic leukemia	Homo sapiens	CVCL_6867
	KOCL-50	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6866
	KOCL-51	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6865
	KOCL-69	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3995
	KOPN-1	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3937
	LN-18	Glioblastoma	Homo sapiens	CVCL_0392
	LN-229	Glioblastoma	Homo sapiens	CVCL_0393
	MA9.3 (MA9.3)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	MA9.6 (MLL-AF9)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	ME-1 [Human leukemia]	Adult acute myeloid leukemia	Homo sapiens	CVCL_2110
	ML-2	Adult acute myeloid leukemia	Homo sapiens	CVCL_1418
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	NB4	Acute promyelocytic leukemia	Homo sapiens	CVCL_0005
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	PL21	Familial adenomatous polyposis	Homo sapiens	CVCL_JM48
	T98G	Glioblastoma	Homo sapiens	CVCL_0556
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	U-87MG ATCC	Glioblastoma	Homo sapiens	CVCL_0022
	U-937	Adult acute monocytic leukemia	Homo sapiens	CVCL_0007
In-vivo Model	For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation.
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene				[15]
Response Summary	Wnt/Beta-catenin-mediated FTO downregulation and underscored the role of m6A modifications of Myc proto-oncogene protein (MYC) mRNA in regulating tumor cell glycolysis and growth.
Target Regulation	Down regulation
Responsed Disease	Solid tumour/cancer		ICD-11: 2A00-2F9Z	Disease Info
Pathway Response	Wnt signaling pathway			hsa04310
	Central carbon metabolism in cancer			hsa05230
	Glycolysis / Gluconeogenesis			hsa00010
Cell Process	Glycolysis
In-vitro Model	NCI-H322	Minimally invasive lung adenocarcinoma	Homo sapiens	CVCL_1556
In-vitro Model	HEK293T	Normal	Homo sapiens	CVCL_0063
In-vivo Model	Mice were randomized into several groups. For the subcutaneous implantation model, 1?×?10⁶ cells were injected subcutaneously into the flank regions of female BALB/c nude mice (4-5 weeks). For lung colonization assays, 1 × 10⁶ cells were injected into the tail vein of female NOD/SCID mice (6-7 weeks), and 6 weeks later the lung was removed and fixed with 10% formalin.
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene				[14]
Response Summary	This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/Myc proto-oncogene protein (MYC)/CEBPA signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling.
Target Regulation	Down regulation
Responsed Disease	Leukaemia		ICD-11: 2B33.4	Disease Info
Responsed Drug	R-2HG		Investigative	Drug Info
Cell Process	Glutamine metabolism
Cell Process	Cell apoptosis
In-vitro Model	8-MG-BA	Glioblastoma	Homo sapiens	CVCL_1052
	A-172	Glioblastoma	Homo sapiens	CVCL_0131
	DK-MG	Glioblastoma	Homo sapiens	CVCL_1173
	GaMG	Glioblastoma	Homo sapiens	CVCL_1226
	HEL	Erythroleukemia	Homo sapiens	CVCL_0001
	Jurkat	T acute lymphoblastic leukemia	Homo sapiens	CVCL_0065
	KOCL-45	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3993
	KOCL-48	Childhood acute monocytic leukemia	Homo sapiens	CVCL_6867
	KOCL-50	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6866
	KOCL-51	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6865
	KOCL-69	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3995
	KOPN-1	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3937
	LN-18	Glioblastoma	Homo sapiens	CVCL_0392
	LN-229	Glioblastoma	Homo sapiens	CVCL_0393
	MA9.3 (MA9.3)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	MA9.6 (MLL-AF9)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	ME-1 [Human leukemia]	Adult acute myeloid leukemia	Homo sapiens	CVCL_2110
	ML-2	Adult acute myeloid leukemia	Homo sapiens	CVCL_1418
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	NB4	Acute promyelocytic leukemia	Homo sapiens	CVCL_0005
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	PL21	Familial adenomatous polyposis	Homo sapiens	CVCL_JM48
	T98G	Glioblastoma	Homo sapiens	CVCL_0556
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	U-87MG ATCC	Glioblastoma	Homo sapiens	CVCL_0022
	U-937	Adult acute monocytic leukemia	Homo sapiens	CVCL_0007
In-vivo Model	For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation.
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene				[16]
Response Summary	miR-96 antagomir could potentially retard the cancerogenesis in colorectal cancer via AMPK-alpha-2-dependent inhibition of FTO and blocking FTO-mediated m6A modification of Myc proto-oncogene protein (MYC).
Target Regulation	Up regulation
Responsed Disease	Colorectal cancer		ICD-11: 2B91	Disease Info
Cell Process	Cell proliferation
Cell Process	Cell apoptosis
In-vitro Model	HCT 8	Colon adenocarcinoma	Homo sapiens	CVCL_2478
	SW480	Colon adenocarcinoma	Homo sapiens	CVCL_0546
	SW620	Colon adenocarcinoma	Homo sapiens	CVCL_0547
In-vivo Model	RC cells SW480 at logarithmic growth phase were prepared into cell suspension with a concentration of about 1 × 10⁷/100 L, which was then injected into the left axilla of nude mice with a 1 ml syringe to establish a subcutaneous mouse xenograft model. Once the tumor volume reached about 50 mm³, the nude mice were injected with miR-96 antagomir or NC antagomir (10 nmol once every 5 days for 5 weeks). After 5 weeks, the mice were euthanized, after which the subcutaneous transplanted tumor was removed, and weighed.
Experiment 5 Reporting the m6A Methylation Regulator of This Target Gene				[17]
Response Summary	GSK3beta inhibited MZF1 expression by mediating FTO-regulated m6A modification of MZF1 and then decreased the proto-oncogene Myc proto-oncogene protein (MYC) expression, thus hampering CRC cell proliferation.
Target Regulation	Down regulation
Responsed Disease	Colorectal cancer		ICD-11: 2B91	Disease Info
Pathway Response	Ubiquitin mediated proteolysis			hsa04120
Cell Process	Cell proliferation
In-vitro Model	SW620	Colon adenocarcinoma	Homo sapiens	CVCL_0547
	SW480	Colon adenocarcinoma	Homo sapiens	CVCL_0546
	HCT 8	Colon adenocarcinoma	Homo sapiens	CVCL_2478
In-vivo Model	Twenty-four specific pathogen free female BALB/c nude mice (age: 6 weeks, weight: 15 ~ 18 g) were purchased from Slac Laboratory Animal Co., Ltd., and subcutaneously injected with SW620 cells stably transfected with oe-NC, oe-GSK3-Beta + oe-NC, or oe-GSK3-Beta + oe-c-Myc to establish a subcutaneous xenograft tumour model in nude mice.
Experiment 6 Reporting the m6A Methylation Regulator of This Target Gene				[18]
Response Summary	FTO has been indicated to interact with Myc proto-oncogene protein (MYC) proto-oncogene, bHLH transcription factor and to enhance its stability by decreasing its m6A level.the aforementioned observations indicate a novel mechanism for the regulation of pancreatic cancer cells by FTO
Target Regulation	Up regulation
Responsed Disease	Pancreatic cancer		ICD-11: 2C10	Disease Info
Cell Process	Cell proliferation
In-vitro Model	BxPC-3	Pancreatic ductal adenocarcinoma	Homo sapiens	CVCL_0186
	HPDE	Normal	Homo sapiens	CVCL_4376
	PANC-1	Pancreatic ductal adenocarcinoma	Homo sapiens	CVCL_0480
	SW1990	Pancreatic adenocarcinoma	Homo sapiens	CVCL_1723
Experiment 7 Reporting the m6A Methylation Regulator of This Target Gene				[8]
Response Summary	This study revealed that m6A methylation is closely related to the poor prognosis of non-small cell lung cancer patients via interference with the TIME, which suggests that m6A plays a role in optimizing individualized immunotherapy management and improving prognosis. The expression levels of METTL3, FTO and YTHDF1 in non-small cell lung cancer were changed. Patients in Cluster 1 had lower immunoscores, higher programmed death-ligand 1 (PD-L1) expression, and shorter overall survival compared to patients in Cluster 2. The Myc proto-oncogene protein (MYC) targets, E2 transcription Factor (E2F) targets were significantly enriched.
Responsed Disease	Non-small-cell lung carcinoma		ICD-11: 2C25.Y	Disease Info
Pathway Response	p53 signaling pathway			hsa04115
	Central carbon metabolism in cancer			hsa05230
	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Experiment 8 Reporting the m6A Methylation Regulator of This Target Gene				[19]
Response Summary	FTO interacts with transcripts of E2F1 and Myc proto-oncogene protein (MYC), inhibition of FTO significantly impairs the translation efficiency of E2F1 and Myc.FTO plays important oncogenic role in regulating cervical cancer cells' proliferation.
Target Regulation	Up regulation
Responsed Disease	Cervical cancer		ICD-11: 2C77	Disease Info
Cell Process	Cell proliferation and migration
In-vitro Model	HeLa	Endocervical adenocarcinoma	Homo sapiens	CVCL_0030
In-vitro Model	SiHa	Cervical squamous cell carcinoma	Homo sapiens	CVCL_0032

Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) [READER]

Regulator Info

*Representative RNA-seq result indicating the expression of this target gene regulated by IGF2BP1*
Cell Line	HepG2 cell line	Homo sapiens
Treatment: siIGF2BP1 HepG2 cells Control: siControl HepG2 cells		GSE161086
Regulation		logFC: -9.94E-01 p-value: 1.72E-04
More Results	Click to View More RNA-seq Results

In total 4 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene				[20]
Response Summary	YBX1 selectively functions in regulating survival of myeloid leukemia cells. YBX1 interacts with insulin-like growth factor 2 messenger RNA (mRNA)-binding proteins (IGF2BPs) and stabilizes m6A-tagged RNA. YBX1 deficiency dysregulates the expression of apoptosis-related genes and promotes mRNA decay of Myc proto-oncogene protein (MYC) and BCL2 in an m6A-dependent manner, which contributes to the defective survival that results from deletion of YBX1.
Target Regulation	Up regulation
Responsed Disease	Myeloid leukaemia		ICD-11: 2B33.1	Disease Info
Cell Process	Cell apoptosis
In-vitro Model	Leukemia stem cell line (Leukemia stem cell line)
	Kasumi-1	Myeloid leukemia with maturation	Homo sapiens	CVCL_0589
	MOLM-13	Adult acute myeloid leukemia	Homo sapiens	CVCL_2119
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	BV-173	Chronic myelogenous leukemia	Homo sapiens	CVCL_0181
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	K-562	Chronic myelogenous leukemia	Homo sapiens	CVCL_0004
	KG-1a	Adult acute myeloid leukemia	Homo sapiens	CVCL_1824
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene				[21]
Response Summary	IGF2BP1 upregulated in GC tissue and acted as a predictor of poor prognosis for GC patients. IGF2BP1 directly interacted with Myc proto-oncogene protein (MYC) mRNA via m6A-dependent manner to by stabilize its stability.
Target Regulation	Up regulation
Responsed Disease	Gastric cancer		ICD-11: 2B72	Disease Info
Pathway Response	Central carbon metabolism in cancer			hsa05230
Pathway Response	Glycolysis / Gluconeogenesis			hsa00010
Cell Process	Aerobic glycolysis
In-vitro Model	SNU-216	Gastric tubular adenocarcinoma	Homo sapiens	CVCL_3946
	MKN45	Gastric adenocarcinoma	Homo sapiens	CVCL_0434
	HGC-27	Gastric carcinoma	Homo sapiens	CVCL_1279
	GES-1	Normal	Homo sapiens	CVCL_EQ22
	AGS	Gastric adenocarcinoma	Homo sapiens	CVCL_0139
In-vivo Model	A total of 5 × 10⁶ transfected MKN-45 cells, stably transfected with sh-IGF2BP1 vector or empty vector were subcutaneously injected into the flank of the mice. Tumor growth was measured every three days, and calculated using the following equation = a × b2/2 (a for longitudinal diameter; and b for latitudinal diameter). Three weeks after injection, mice were sacrificed.
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene				[22]
Response Summary	In contrast to the mRNA-decay-promoting function of YTH domain-containing family protein 2, IGF2BPs promote the stability and storage of their target mRNAs (for example, MYC) in an m6A-dependent manner under normal and stress conditions and therefore affect gene expression output. Four representative high confidence targets, including Myc proto-oncogene protein (MYC), FSCN1, TK1, and MARCKSL1, exhibit strong binding with IGF2BPs around their m6A motifs in control cells. Knocking down of each individual IGF2BPs in Hela (cervical cancer) and HepG2 (liver cancer) cells significantly repressed MYC expression.
Responsed Disease	Hepatocellular carcinoma		ICD-11: 2C12.02	Disease Info
Cell Process	RNA decay
In-vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027
	HEK293T	Normal	Homo sapiens	CVCL_0063
	HeLa	Endocervical adenocarcinoma	Homo sapiens	CVCL_0030
	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene				[23]
Response Summary	Hypoxia-induced lncRNA KB-1980E6.3 is involved in the self-renewal and stemness maintenance of breast cancer stem cells by recruiting IGF2BP1 to regulate Myc proto-oncogene protein (MYC) mRNA stability.
Target Regulation	Up regulation
Responsed Disease	Breast cancer		ICD-11: 2C60	Disease Info
Pathway Response	Signaling pathways regulating pluripotency of stem cells			hsa04550
In-vitro Model	BT-474	Invasive breast carcinoma	Homo sapiens	CVCL_0179
	BT-549	Invasive breast carcinoma	Homo sapiens	CVCL_1092
	HEK293T	Normal	Homo sapiens	CVCL_0063
	Hs 578T	Invasive breast carcinoma	Homo sapiens	CVCL_0332
	MCF-7	Invasive breast carcinoma	Homo sapiens	CVCL_0031
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens	CVCL_0062
	MDA-MB-453	Breast adenocarcinoma	Homo sapiens	CVCL_0418
	MDA-MB-468	Breast adenocarcinoma	Homo sapiens	CVCL_0419
	T-47D	Invasive breast carcinoma	Homo sapiens	CVCL_0553
In-vivo Model	The enriched mammosphere cells derived from engineered BT549 and Hs578T with silenced lncRNA KB-1980E6.3 (shKB/vector), BT549, and Hs578T with lncRNA KB-1980E6.3 knockdown combined with ectopic c-Myc (shKB/c-Myc), BT549, and Hs578T with silenced IGF2BP1 (shIGF2BP1/vector), BT549, and Hs578T with knocked down IGF2BP1 combined with ectopic c-Myc (shIGF2BP1/c-Myc), and BT549, and Hs578T/shNC/vector control cells were used in Xenograft experiments. Three doses (1 × 10⁵, 1 × 10⁴ and 1 × 10³) of spheres derived from the engineered Hs578T and 1 × 10⁵ of spheres derived from the engineered BT549 were subcutaneously inoculated into 4- to 6-week-old female nude mice (n = 5 per group). Mice were then treated with either bevacizumab (10 mg/kg every 3 days) to form a hypoxic tumor microenvironment or vehicle PBS to form a non-hypoxic condition

Methyltransferase-like 14 (METTL14) [WRITER]

Regulator Info

*Representative RNA-seq result indicating the expression of this target gene regulated by METTL14*
Cell Line	MDA-MB-231	Homo sapiens
Treatment: siMETTL14 MDA-MB-231 cells Control: MDA-MB-231 cells		GSE81164
Regulation		logFC: 1.27E+00 p-value: 6.21E-24
More Results	Click to View More RNA-seq Results

In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene				[24]
Response Summary	METTL14 in normal myelopoiesis and AML pathogenesis, as featured by blocking myeloid differentiation and promoting self-renewal of normal HSPCs and LSCs/LICs. METTL14 exerts its oncogenic role by regulating its mRNA targets (e.g., MYB and Myc proto-oncogene protein (MYC)) through m6A modification, while the protein itself is negatively regulated by SPI1.
Target Regulation	Up regulation
Responsed Disease	Acute myeloid leukaemia		ICD-11: 2A60	Disease Info
Cell Process	Cell survival/proliferation
In-vitro Model	HEK293T	Normal	Homo sapiens	CVCL_0063
	HSPC (Human hematopoietic stem cell)
	MNC (Cord blood pluripotent stem cells)
	OP9	Normal	Mus musculus	CVCL_4398
	U-937	Adult acute monocytic leukemia	Homo sapiens	CVCL_0007
In-vivo Model	Lin^- HSPCs were purified from BM of wildtype mice and 0.1×10⁶ cells were seeded in 2 mL OP9 medium onto the OP9 cells with the addition of 10 ng/mL mouse IL-3, 10 ng/mL human IL-6, 10 ng/mL mouse IL-7, 10 ng/mL mouse Flt-3L, and 50 ng/mL mouse stem cell factor (SCF).

Methyltransferase-like 5 (METTL5) [WRITER]

Regulator Info

*Representative RNA-seq result indicating the expression of this target gene regulated by METTL5*
Cell Line	Mouse liver cells	Mus musculus
Treatment: METTL5 knockout liver cells Control: WT liver cells		GSE174418
Regulation		logFC: 2.11E+00 p-value: 1.69E-05
More Results	Click to View More RNA-seq Results

In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene			[25]
Response Summary	The study revealed important roles for METTL5 in the development of pancreatic cancer and present the METTL5/Myc proto-oncogene protein (MYC) axis as a novel therapeutic strategy for treatment.
Responsed Disease	Pancreatic cancer	ICD-11: 2C10	Disease Info
Cell Process	Cell proliferation
	Cell migration
	Cell invasion

Wilms tumor 1-associating protein (WTAP) [WRITER]

Regulator Info

*Representative RNA-seq result indicating the expression of this target gene regulated by WTAP*
Cell Line	mice hepatocyte	Mus musculus
Treatment: Wtap Hknockout mice hepatocyte Control: Wtap flox/flox mice hepatocyte		GSE168850
Regulation		logFC: 2.89E+00 p-value: 1.82E-04
More Results	Click to View More RNA-seq Results

In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene				[26]
Response Summary	WTAP made acute myeloid leukemia cells resistant to daunorubicin. In further investigations, m6A methylation level was downregulated when knocking down WTAP, and Myc proto-oncogene protein (MYC) was upregulated due to the decreased m6A methylation of MYC mRNA.
Target Regulation	Up regulation
Responsed Disease	Acute myeloid leukaemia		ICD-11: 2A60	Disease Info
Responsed Drug	Daunorubicin		Approved	Drug Info
Cell Process	Cell cycle
	Cell proliferation
	Cell apoptosis
In-vitro Model	K-562	Chronic myelogenous leukemia	Homo sapiens	CVCL_0004
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064

Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) [READER]

Regulator Info

In total 4 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene				[20]
Response Summary	YBX1 selectively functions in regulating survival of myeloid leukemia cells. YBX1 interacts with insulin-like growth factor 2 messenger RNA (mRNA)-binding proteins (IGF2BPs) and stabilizes m6A-tagged RNA. YBX1 deficiency dysregulates the expression of apoptosis-related genes and promotes mRNA decay of Myc proto-oncogene protein (MYC) and BCL2 in an m6A-dependent manner, which contributes to the defective survival that results from deletion of YBX1.
Target Regulation	Up regulation
Responsed Disease	Myeloid leukaemia		ICD-11: 2B33.1	Disease Info
Cell Process	Cell apoptosis
In-vitro Model	Leukemia stem cell line (Leukemia stem cell line)
	Kasumi-1	Myeloid leukemia with maturation	Homo sapiens	CVCL_0589
	MOLM-13	Adult acute myeloid leukemia	Homo sapiens	CVCL_2119
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	BV-173	Chronic myelogenous leukemia	Homo sapiens	CVCL_0181
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	K-562	Chronic myelogenous leukemia	Homo sapiens	CVCL_0004
	KG-1a	Adult acute myeloid leukemia	Homo sapiens	CVCL_1824
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene				[27]
Response Summary	LINRIS blocked K139 ubiquitination of IGF2BP2, maintaining its stability. This process prevented the degradation of IGF2BP2 through the autophagy-lysosome pathway (ALP). The LINRIS-IGF2BP2-Myc proto-oncogene protein (MYC) axis promotes the progression of Colorectal cancer and is a promising therapeutic target. MYC-mediated glycolysis was influenced by the interaction between LINRIS and IGF2BP2.
Target Regulation	Up regulation
Responsed Disease	Colorectal cancer		ICD-11: 2B91	Disease Info
Pathway Response	Ubiquitin mediated proteolysis			hsa04120
Pathway Response	Glycolysis / Gluconeogenesis			hsa00010
Cell Process	Autophagy-lysosome pathway
	Ubiquitination
	Glycolysis
In-vitro Model	DLD-1	Colon adenocarcinoma	Homo sapiens	CVCL_0248
In-vitro Model	HCT 116	Colon carcinoma	Homo sapiens	CVCL_0291
In-vivo Model	For the orthotopic models, 2 × 10⁶ cells with negative control (NC, sh-NC), sh-1 or sh-2 in 0.5 mL of PBS were subcutaneously injected into the dorsal flank of 2 mice respectively. Then 15 mice were separated into 3 groups (sh-NC, sh-1 and sh-2), of which the tumor pieces were tied to the base of the ceca. The growth of the tumors was monitored every 2 weeks after intraperitoneal injection of D-luciferin with a Xenogen IVIS 100 Bioluminescent Imaging System.
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene				[28]
Response Summary	LncRNA-PACERR which bound to IGF2BP2 acts as an m6A-dependent manner to enhance the stability of KLF12 and Myc proto-oncogene protein (MYC) in cytoplasm. This study found that LncRNA-PACERR functions as key regulator of TAMs in PDAC microenvironment and revealed the novel mechanisms in cytoplasm and in nucleus.
Target Regulation	Up regulation
Responsed Disease	Pancreatic ductal adenocarcinoma		ICD-11: 2C10.0	Disease Info
Pathway Response	mRNA surveillance pathway			hsa03015
Pathway Response	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	PATU-8988 (Human pancreatic adenocarcinoma cell)
	PANC-1	Pancreatic ductal adenocarcinoma	Homo sapiens	CVCL_0480
	HEK293T	Normal	Homo sapiens	CVCL_0063
	37 (Pancreatic cancer cell)
In-vivo Model	BALB/c nude mice which were co-injected with THP-1 cells and PATU-8988 cells subcutaneously.
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene				[22]
Response Summary	In contrast to the mRNA-decay-promoting function of YTH domain-containing family protein 2, IGF2BPs promote the stability and storage of their target mRNAs (for example, MYC) in an m6A-dependent manner under normal and stress conditions and therefore affect gene expression output. Four representative high confidence targets, including Myc proto-oncogene protein (MYC), FSCN1, TK1, and MARCKSL1, exhibit strong binding with IGF2BPs around their m6A motifs in control cells. Knocking down of each individual IGF2BPs in Hela (cervical cancer) and HepG2 (liver cancer) cells significantly repressed MYC expression.
Responsed Disease	Hepatocellular carcinoma		ICD-11: 2C12.02	Disease Info
Cell Process	RNA decay
In-vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027
	HEK293T	Normal	Homo sapiens	CVCL_0063
	HeLa	Endocervical adenocarcinoma	Homo sapiens	CVCL_0030
	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027

Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) [READER]

Regulator Info

In total 3 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene				[12]
Response Summary	The m6A reader YTHDF2 stabilized Myc proto-oncogene protein (MYC) mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivo glioblastoma growth. YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2-MYC-IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.
Target Regulation	Up regulation
Responsed Disease	Glioma		ICD-11: 2A00.0	Disease Info
Pathway Response	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	()
	HNP1 (A human neural progenitor cell)
	NHA (Normal human astrocytes)
	NSC11 (Pluripotent derived neural progenitor cell)
In-vivo Model	For in vivo drug treatment studies, intracranial xenografts were generated by implanting 5000 patient-derived GSCs (387 and 4121) into the right cerebral cortex of NSG mice as described above.
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene				[20]
Response Summary	YBX1 selectively functions in regulating survival of myeloid leukemia cells. YBX1 interacts with insulin-like growth factor 2 messenger RNA (mRNA)-binding proteins (IGF2BPs) and stabilizes m6A-tagged RNA. YBX1 deficiency dysregulates the expression of apoptosis-related genes and promotes mRNA decay of Myc proto-oncogene protein (MYC) and BCL2 in an m6A-dependent manner, which contributes to the defective survival that results from deletion of YBX1.
Target Regulation	Up regulation
Responsed Disease	Myeloid leukaemia		ICD-11: 2B33.1	Disease Info
Cell Process	Cell apoptosis
In-vitro Model	Leukemia stem cell line (Leukemia stem cell line)
	Kasumi-1	Myeloid leukemia with maturation	Homo sapiens	CVCL_0589
	MOLM-13	Adult acute myeloid leukemia	Homo sapiens	CVCL_2119
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	BV-173	Chronic myelogenous leukemia	Homo sapiens	CVCL_0181
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	K-562	Chronic myelogenous leukemia	Homo sapiens	CVCL_0004
	KG-1a	Adult acute myeloid leukemia	Homo sapiens	CVCL_1824
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene				[22]
Response Summary	In contrast to the mRNA-decay-promoting function of YTH domain-containing family protein 2, IGF2BPs promote the stability and storage of their target mRNAs (for example, MYC) in an m6A-dependent manner under normal and stress conditions and therefore affect gene expression output. Four representative high confidence targets, including Myc proto-oncogene protein (MYC), FSCN1, TK1, and MARCKSL1, exhibit strong binding with IGF2BPs around their m6A motifs in control cells. Knocking down of each individual IGF2BPs in Hela (cervical cancer) and HepG2 (liver cancer) cells significantly repressed MYC expression.
Responsed Disease	Hepatocellular carcinoma		ICD-11: 2C12.02	Disease Info
Cell Process	RNA decay
In-vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027
	HEK293T	Normal	Homo sapiens	CVCL_0063
	HeLa	Endocervical adenocarcinoma	Homo sapiens	CVCL_0030
	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027

Insulin-like growth factor-binding protein 3 (IGFBP3) [READER]

Regulator Info

In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene			[12]
Response Summary	YTHDF2 depletion downregulated IGFBP3 mRNA and protein levels, without affecting its mRNA stability. YTHDF2 regulated IGFBP3 levels via Myc proto-oncogene protein (MYC) in glioblastoma stem cells.
Responsed Disease	Glioblastoma	ICD-11: 2A00.00	Disease Info
In-vitro Model	ENSA (A human embryonic stem derived neural progenitor cell)
	HNP1 (A human neural progenitor cell)
	NSC11 (Pluripotent derived neural progenitor cell)
	NHA (Normal human astrocytes)
In-vivo Model	Implanting 5000 human derived GSCs into the right cerebral cortex of NSG mice at a depth of 3.5 mm under a University of California, San Diego Institutional Animal Care and Use Committee (IACUC) approved protocol. Brains were harvested and fixed in 4% formaldehyde, cryopreserved in 30% sucrose, and then cryosectioned. Hematoxylin and eosin (H&E) staining was performed on sections for histological analysis. In parallel survival experiments, mice were observed until the development of neurological signs. For in vivo drug treatment studies, intracranial xenografts were generated by implanting 5000 patient-derived GSCs (387 and 4121) into the right cerebral cortex of NSG mice as described above. Mice recovered for 7 days were randomly assigned into drug vs. treatment group by a blinded investigator. Mice were then treated daily with either vehicle (25 mM Tartaric acid) or 50 mg/kg linsitinib by oral gavage.

Brain cancer [ICD-11: 2A00]

Disease Info

In total 5 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[14]
Response Summary	This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/Myc proto-oncogene protein (MYC)/CEBPA signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling.
Responsed Disease	Glioma [ICD-11: 2A00.0]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Down regulation
Responsed Drug	R-2HG		Investigative	Drug Info
Cell Process	Glutamine metabolism
	Cell apoptosis
In-vitro Model	8-MG-BA	Glioblastoma	Homo sapiens	CVCL_1052
	A-172	Glioblastoma	Homo sapiens	CVCL_0131
	DK-MG	Glioblastoma	Homo sapiens	CVCL_1173
	GaMG	Glioblastoma	Homo sapiens	CVCL_1226
	HEL	Erythroleukemia	Homo sapiens	CVCL_0001
	Jurkat	T acute lymphoblastic leukemia	Homo sapiens	CVCL_0065
	KOCL-45	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3993
	KOCL-48	Childhood acute monocytic leukemia	Homo sapiens	CVCL_6867
	KOCL-50	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6866
	KOCL-51	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6865
	KOCL-69	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3995
	KOPN-1	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3937
	LN-18	Glioblastoma	Homo sapiens	CVCL_0392
	LN-229	Glioblastoma	Homo sapiens	CVCL_0393
	MA9.3 (MA9.3)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	MA9.6 (MLL-AF9)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	ME-1 [Human leukemia]	Adult acute myeloid leukemia	Homo sapiens	CVCL_2110
	ML-2	Adult acute myeloid leukemia	Homo sapiens	CVCL_1418
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	NB4	Acute promyelocytic leukemia	Homo sapiens	CVCL_0005
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	PL21	Familial adenomatous polyposis	Homo sapiens	CVCL_JM48
	T98G	Glioblastoma	Homo sapiens	CVCL_0556
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	U-87MG ATCC	Glioblastoma	Homo sapiens	CVCL_0022
	U-937	Adult acute monocytic leukemia	Homo sapiens	CVCL_0007
In-vivo Model	For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation.
Experiment 2 Reporting the m6A-centered Disease Response				[12]
Response Summary	The m6A reader YTHDF2 stabilized Myc proto-oncogene protein (MYC) mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivo glioblastoma growth. YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2-MYC-IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.
Responsed Disease	Glioma [ICD-11: 2A00.0]
Target Regulator	Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	()
	HNP1 (A human neural progenitor cell)
	NHA (Normal human astrocytes)
	NSC11 (Pluripotent derived neural progenitor cell)
In-vivo Model	For in vivo drug treatment studies, intracranial xenografts were generated by implanting 5000 patient-derived GSCs (387 and 4121) into the right cerebral cortex of NSG mice as described above.
Experiment 3 Reporting the m6A-centered Disease Response				[12]
Response Summary	YTHDF2 depletion downregulated IGFBP3 mRNA and protein levels, without affecting its mRNA stability. YTHDF2 regulated IGFBP3 levels via Myc proto-oncogene protein (MYC) in glioblastoma stem cells.
Responsed Disease	Glioblastoma [ICD-11: 2A00.00]
Target Regulator	Insulin-like growth factor-binding protein 3 (IGFBP3)		READER	Regulator Info
In-vitro Model	ENSA (A human embryonic stem derived neural progenitor cell)
	HNP1 (A human neural progenitor cell)
	NSC11 (Pluripotent derived neural progenitor cell)
	NHA (Normal human astrocytes)
In-vivo Model	Implanting 5000 human derived GSCs into the right cerebral cortex of NSG mice at a depth of 3.5 mm under a University of California, San Diego Institutional Animal Care and Use Committee (IACUC) approved protocol. Brains were harvested and fixed in 4% formaldehyde, cryopreserved in 30% sucrose, and then cryosectioned. Hematoxylin and eosin (H&E) staining was performed on sections for histological analysis. In parallel survival experiments, mice were observed until the development of neurological signs. For in vivo drug treatment studies, intracranial xenografts were generated by implanting 5000 patient-derived GSCs (387 and 4121) into the right cerebral cortex of NSG mice as described above. Mice recovered for 7 days were randomly assigned into drug vs. treatment group by a blinded investigator. Mice were then treated daily with either vehicle (25 mM Tartaric acid) or 50 mg/kg linsitinib by oral gavage.
Experiment 4 Reporting the m6A-centered Disease Response				[12]
Response Summary	The IGF1/IGF1R inhibitor, linsitinib for further investigation based upon the role of the IGF pathway member, IGFBP3, as a downstream effector of YTHDF2-Myc proto-oncogene protein (MYC) axis in GSCs. Inhibiting glioblastoma stem cells viability without affecting NSCs and impairing in vivo glioblastoma growth.
Responsed Disease	Glioblastoma [ICD-11: 2A00.00]
Target Regulator	YTH domain-containing family protein 2 (YTHDF2)		READER	Regulator Info
Target Regulation	Up regulation
Responsed Drug	Linsitinib		Phase 3	Drug Info
In-vitro Model	NSC11 (Pluripotent derived neural progenitor cell)
	NHA (Normal human astrocytes)
	HNP1 (A human neural progenitor cell)
	ENSA (A human embryonic stem derived neural progenitor cell)
In-vivo Model	Implanting 5000 human derived GSCs into the right cerebral cortex of NSG mice at a depth of 3.5 mm under a University of California, San Diego Institutional Animal Care and Use Committee (IACUC) approved protocol. Brains were harvested and fixed in 4% formaldehyde, cryopreserved in 30% sucrose, and then cryosectioned. Hematoxylin and eosin (H&E) staining was performed on sections for histological analysis. In parallel survival experiments, mice were observed until the development of neurological signs. For in vivo drug treatment studies, intracranial xenografts were generated by implanting 5000 patient-derived GSCs (387 and 4121) into the right cerebral cortex of NSG mice as described above. Mice recovered for 7 days were randomly assigned into drug vs. treatment group by a blinded investigator. Mice were then treated daily with either vehicle (25 mM Tartaric acid) or 50 mg/kg linsitinib by oral gavage.
Experiment 5 Reporting the m6A-centered Disease Response				[12]
Response Summary	The m6A reader YTHDF2 stabilized Myc proto-oncogene protein (MYC) mRNA specifically in cancer stem cells. Given the challenge of targeting MYC, YTHDF2 presents a therapeutic target to perturb MYC signaling in glioblastoma. The IGF1/IGF1R inhibitor linsitinib preferentially targeted YTHDF2-expressing cells, inhibiting GSC viability without affecting NSCs and impairing in vivo glioblastoma growth. YTHDF2 links RNA epitranscriptomic modifications and GSC growth, laying the foundation for the YTHDF2-MYC-IGFBP3 axis as a specific and novel therapeutic target in glioblastoma.
Responsed Disease	Glioma [ICD-11: 2A00.0]
Target Regulator	YTH domain-containing family protein 2 (YTHDF2)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	()
	HNP1 (A human neural progenitor cell)
	NHA (Normal human astrocytes)
	NSC11 (Pluripotent derived neural progenitor cell)
In-vivo Model	For in vivo drug treatment studies, intracranial xenografts were generated by implanting 5000 patient-derived GSCs (387 and 4121) into the right cerebral cortex of NSG mice as described above.

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Disease Info

In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[]
Response Summary	In this review, we discuss the specific roles of m6A "writers", "erasers", and "readers" in normal physiology and how their altered expression promotes tumorigenesis. We also describe the potential of exploiting the aberrant expression of these enzymes for cancer diagnosis, prognosis, and the development of novel therapies. The abnormal expression of m6A regulatory enzymes affects m6A abundance and consequently dysregulates the expression of tumor suppressor genes and oncogenes, including Myc proto-oncogene protein (MYC), SOCS2, ADAM19, and PTEN.
Responsed Disease	Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Experiment 2 Reporting the m6A-centered Disease Response				[15]
Response Summary	Wnt/Beta-catenin-mediated FTO downregulation and underscored the role of m6A modifications of Myc proto-oncogene protein (MYC) mRNA in regulating tumor cell glycolysis and growth.
Responsed Disease	Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Wnt signaling pathway			hsa04310
	Central carbon metabolism in cancer			hsa05230
	Glycolysis / Gluconeogenesis			hsa00010
Cell Process	Glycolysis
In-vitro Model	NCI-H322	Minimally invasive lung adenocarcinoma	Homo sapiens	CVCL_1556
	HEK293T	Normal	Homo sapiens	CVCL_0063
In-vivo Model	Mice were randomized into several groups. For the subcutaneous implantation model, 1?×?10⁶ cells were injected subcutaneously into the flank regions of female BALB/c nude mice (4-5 weeks). For lung colonization assays, 1 × 10⁶ cells were injected into the tail vein of female NOD/SCID mice (6-7 weeks), and 6 weeks later the lung was removed and fixed with 10% formalin.

Acute myeloid leukaemia [ICD-11: 2A60]

Disease Info

In total 4 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[24]
Response Summary	METTL14 in normal myelopoiesis and AML pathogenesis, as featured by blocking myeloid differentiation and promoting self-renewal of normal HSPCs and LSCs/LICs. METTL14 exerts its oncogenic role by regulating its mRNA targets (e.g., MYB and Myc proto-oncogene protein (MYC)) through m6A modification, while the protein itself is negatively regulated by SPI1.
Responsed Disease	Acute myeloid leukaemia [ICD-11: 2A60]
Target Regulator	Methyltransferase-like 14 (METTL14)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell survival/proliferation
In-vitro Model	HEK293T	Normal	Homo sapiens	CVCL_0063
	HSPC (Human hematopoietic stem cell)
	MNC (Cord blood pluripotent stem cells)
	OP9	Normal	Mus musculus	CVCL_4398
	U-937	Adult acute monocytic leukemia	Homo sapiens	CVCL_0007
In-vivo Model	Lin^- HSPCs were purified from BM of wildtype mice and 0.1×10⁶ cells were seeded in 2 mL OP9 medium onto the OP9 cells with the addition of 10 ng/mL mouse IL-3, 10 ng/mL human IL-6, 10 ng/mL mouse IL-7, 10 ng/mL mouse Flt-3L, and 50 ng/mL mouse stem cell factor (SCF).
Experiment 2 Reporting the m6A-centered Disease Response				[1]
Response Summary	METTL3 depletion in human myeloid leukemia cell lines induces cell differentiation and apoptosis and delays leukemia progression in recipient mice in vivo. Single-nucleotide-resolution mapping of m6A coupled with ribosome profiling reveals that m6A promotes the translation of Myc proto-oncogene protein (MYC), BCL2 and PTEN mRNAs in the human acute myeloid leukemia MOLM-13 cell line. Moreover, loss of METTL3 leads to increased levels of phosphorylated AKT.
Responsed Disease	Acute myeloid leukaemia [ICD-11: 2A60]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell differentiation and apoptosis
	Apoptosis (hsa04210)
In-vitro Model	HSPC (Human hematopoietic stem cell)
In-vivo Model	500,000 selected cells were injected via tail vein or retro-orbital route into female NSG (6-8 week old) recipient mice that had been sublethally irradiated with 475 cGy one day before transplantation.
Experiment 3 Reporting the m6A-centered Disease Response				[2]
Response Summary	METTL3 level was slightly increased in AML-M5 patients,and its expression was significantly higher in immature cells than in mature monocytes.METTL3 acts as an oncogene in MOLM13 cells by upregulating Myc proto-oncogene protein (MYC) expression.
Responsed Disease	Acute myeloid leukaemia [ICD-11: 2A60]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation
In-vitro Model	MOLM-13	Adult acute myeloid leukemia	Homo sapiens	CVCL_2119
Experiment 4 Reporting the m6A-centered Disease Response				[26]
Response Summary	WTAP made acute myeloid leukemia cells resistant to daunorubicin. In further investigations, m6A methylation level was downregulated when knocking down WTAP, and Myc proto-oncogene protein (MYC) was upregulated due to the decreased m6A methylation of MYC mRNA.
Responsed Disease	Acute myeloid leukaemia [ICD-11: 2A60]
Target Regulator	Wilms tumor 1-associating protein (WTAP)		WRITER	Regulator Info
Target Regulation	Up regulation
Responsed Drug	Daunorubicin		Approved	Drug Info
Cell Process	Cell cycle
	Cell proliferation
	Cell apoptosis
In-vitro Model	K-562	Chronic myelogenous leukemia	Homo sapiens	CVCL_0004
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064

Malignant haematopoietic neoplasm [ICD-11: 2B33]

Disease Info

In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[14]
Response Summary	This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/Myc proto-oncogene protein (MYC)/CEBPA signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling.
Responsed Disease	Leukaemia [ICD-11: 2B33.4]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Down regulation
Responsed Drug	R-2HG		Investigative	Drug Info
Cell Process	Glutamine metabolism
Cell Process	Cell apoptosis
In-vitro Model	8-MG-BA	Glioblastoma	Homo sapiens	CVCL_1052
	A-172	Glioblastoma	Homo sapiens	CVCL_0131
	DK-MG	Glioblastoma	Homo sapiens	CVCL_1173
	GaMG	Glioblastoma	Homo sapiens	CVCL_1226
	HEL	Erythroleukemia	Homo sapiens	CVCL_0001
	Jurkat	T acute lymphoblastic leukemia	Homo sapiens	CVCL_0065
	KOCL-45	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3993
	KOCL-48	Childhood acute monocytic leukemia	Homo sapiens	CVCL_6867
	KOCL-50	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6866
	KOCL-51	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6865
	KOCL-69	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3995
	KOPN-1	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3937
	LN-18	Glioblastoma	Homo sapiens	CVCL_0392
	LN-229	Glioblastoma	Homo sapiens	CVCL_0393
	MA9.3 (MA9.3)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	MA9.6 (MLL-AF9)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	ME-1 [Human leukemia]	Adult acute myeloid leukemia	Homo sapiens	CVCL_2110
	ML-2	Adult acute myeloid leukemia	Homo sapiens	CVCL_1418
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	NB4	Acute promyelocytic leukemia	Homo sapiens	CVCL_0005
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	PL21	Familial adenomatous polyposis	Homo sapiens	CVCL_JM48
	T98G	Glioblastoma	Homo sapiens	CVCL_0556
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	U-87MG ATCC	Glioblastoma	Homo sapiens	CVCL_0022
	U-937	Adult acute monocytic leukemia	Homo sapiens	CVCL_0007
In-vivo Model	For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation.
Experiment 2 Reporting the m6A-centered Disease Response				[20]
Response Summary	YBX1 selectively functions in regulating survival of myeloid leukemia cells. YBX1 interacts with insulin-like growth factor 2 messenger RNA (mRNA)-binding proteins (IGF2BPs) and stabilizes m6A-tagged RNA. YBX1 deficiency dysregulates the expression of apoptosis-related genes and promotes mRNA decay of Myc proto-oncogene protein (MYC) and BCL2 in an m6A-dependent manner, which contributes to the defective survival that results from deletion of YBX1.
Responsed Disease	Myeloid leukaemia [ICD-11: 2B33.1]
Target Regulator	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)		READER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell apoptosis
In-vitro Model	Leukemia stem cell line (Leukemia stem cell line)
	Kasumi-1	Myeloid leukemia with maturation	Homo sapiens	CVCL_0589
	MOLM-13	Adult acute myeloid leukemia	Homo sapiens	CVCL_2119
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	BV-173	Chronic myelogenous leukemia	Homo sapiens	CVCL_0181
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	K-562	Chronic myelogenous leukemia	Homo sapiens	CVCL_0004
	KG-1a	Adult acute myeloid leukemia	Homo sapiens	CVCL_1824

Head and neck squamous carcinoma [ICD-11: 2B6E]

Disease Info

In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[3]
Response Summary	In oral squamous cell carcinoma, YTH N6-methyladenosine RNA binding protein 1 (YTH domain family, member 1 [YTHDF1]) mediated the m6A-increased stability of Myc proto-oncogene protein (MYC) mRNA catalyzed by METTL3.
Responsed Disease	Oral squamous cell carcinoma [ICD-11: 2B6E.0]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Pathway Response	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	CAL-27	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1107
	NHOK (Normal oral keratinocytes)
	SCC-15	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1681
	SCC-25	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1682
	TSCCa	Endocervical adenocarcinoma	Homo sapiens	CVCL_VL15
In-vivo Model	The stable transfection of SCC25 cells (1 × 10⁷ cells in 0.1 mL) with lenti-sh-METTL3 or blank vectors was injected subcutaneously into BALB/c nude mice.
Experiment 2 Reporting the m6A-centered Disease Response				[3]
Response Summary	In oral squamous cell carcinoma, YTH N6-methyladenosine RNA binding protein 1 (YTH domain family, member 1 [YTHDF1]) mediated the m6A-increased stability of Myc proto-oncogene protein (MYC) mRNA catalyzed by METTL3.
Responsed Disease	Oral squamous cell carcinoma [ICD-11: 2B6E.0]
Target Regulator	YTH domain-containing family protein 1 (YTHDF1)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	CAL-27	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1107
	NHOK (Normal oral keratinocytes)
	SCC-15	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1681
	SCC-25	Tongue squamous cell carcinoma	Homo sapiens	CVCL_1682
	TSCCa	Endocervical adenocarcinoma	Homo sapiens	CVCL_VL15
In-vivo Model	The stable transfection of SCC25 cells (1 × 10⁷ cells in 0.1 mL) with lenti-sh-METTL3 or blank vectors was injected subcutaneously into BALB/c nude mice.

Gastric cancer [ICD-11: 2B72]

Disease Info

In total 4 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[21]
Response Summary	IGF2BP1 upregulated in GC tissue and acted as a predictor of poor prognosis for GC patients. IGF2BP1 directly interacted with Myc proto-oncogene protein (MYC) mRNA via m6A-dependent manner to by stabilize its stability.
Responsed Disease	Gastric cancer [ICD-11: 2B72]
Target Regulator	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	Central carbon metabolism in cancer			hsa05230
Pathway Response	Glycolysis / Gluconeogenesis			hsa00010
Cell Process	Aerobic glycolysis
In-vitro Model	SNU-216	Gastric tubular adenocarcinoma	Homo sapiens	CVCL_3946
	MKN45	Gastric adenocarcinoma	Homo sapiens	CVCL_0434
	HGC-27	Gastric carcinoma	Homo sapiens	CVCL_1279
	GES-1	Normal	Homo sapiens	CVCL_EQ22
	AGS	Gastric adenocarcinoma	Homo sapiens	CVCL_0139
In-vivo Model	A total of 5 × 10⁶ transfected MKN-45 cells, stably transfected with sh-IGF2BP1 vector or empty vector were subcutaneously injected into the flank of the mice. Tumor growth was measured every three days, and calculated using the following equation = a × b2/2 (a for longitudinal diameter; and b for latitudinal diameter). Three weeks after injection, mice were sacrificed.
Experiment 2 Reporting the m6A-centered Disease Response				[4]
Response Summary	In gastric cancer, several component molecules (e.g., MCM5, MCM6, etc.) of Myc proto-oncogene protein (MYC) target genes were mediated by METTL3 via altered m6A modification.
Responsed Disease	Gastric cancer [ICD-11: 2B72]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
In-vitro Model	GES-1	Normal	Homo sapiens	CVCL_EQ22
	HGC-27	Gastric carcinoma	Homo sapiens	CVCL_1279
	MGC-803	Gastric mucinous adenocarcinoma	Homo sapiens	CVCL_5334
	MKN45	Gastric adenocarcinoma	Homo sapiens	CVCL_0434
	MKN74	Gastric tubular adenocarcinoma	Homo sapiens	CVCL_2791
	pGCC (Primary GC cells)
	SGC-7901	Gastric carcinoma	Homo sapiens	CVCL_0520
In-vivo Model	A total of 2 × 10⁶ GC cells were injected into the flank of nude mice in a 1:1 suspension of BD Matrigel (BD Biosciences) in phosphate-buffered saline (PBS) solution.
Experiment 3 Reporting the m6A-centered Disease Response				[5]
Response Summary	METTL3 enhanced Myc proto-oncogene protein (MYC) m6A methylation and increased MYC translation, which could potentiate the proliferation, migration and invasion of gastric cancer cells.
Responsed Disease	Gastric cancer [ICD-11: 2B72]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
	Cell apoptosis
In-vitro Model	AGS	Gastric adenocarcinoma	Homo sapiens	CVCL_0139
	AZ-521	Duodenal adenocarcinoma	Homo sapiens	CVCL_2862
	GES-1	Normal	Homo sapiens	CVCL_EQ22
	MKN45	Gastric adenocarcinoma	Homo sapiens	CVCL_0434
	SGC-7901	Gastric carcinoma	Homo sapiens	CVCL_0520
In-vivo Model	The GC cell line MKN-45 stably infected with lentivirus expressing sh-HBXIP was prepared into 5 × 10⁷ cells/mL cell suspension.
Experiment 4 Reporting the m6A-centered Disease Response				[5]
Response Summary	Expressions of HBXIP, METTL3 and Myc proto-oncogene protein (MYC) were all determined to be upregulated in both GC tissues and cells. HBXIP plays an oncogenic role in GC via METTL3-mediated MYC mRNA m6A modification.
Responsed Disease	Gastric cancer [ICD-11: 2B72]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
	Cell apoptosis
In-vitro Model	SGC-7901	Gastric carcinoma	Homo sapiens	CVCL_0520
	MKN45	Gastric adenocarcinoma	Homo sapiens	CVCL_0434
	GES-1	Normal	Homo sapiens	CVCL_EQ22
	AZ-521	Duodenal adenocarcinoma	Homo sapiens	CVCL_2862
	AGS	Gastric adenocarcinoma	Homo sapiens	CVCL_0139
In-vivo Model	The GC cell line MKN-45 stably infected with lentivirus expressing sh-HBXIP was prepared into 5 × 10⁷ cells/mL cell suspension. The cell suspension was injected into the left axilla of nude mice using a 1 mL syringe as the sh-HBXIP group (n = 6). The GC cell line MKN-45 infected with the lentivirus expressing sh-NC was dispersed into the cell suspension, which was injected into nude mice as the sh-NC group (n = 6). Tumor growth was observed and data were recorded after inoculation. On the 26th day, all nude mice were euthanized by cervical dislocation and the tumors were resected and weighed.

Colorectal cancer [ICD-11: 2B91]

Disease Info

In total 4 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[16]
Response Summary	miR-96 antagomir could potentially retard the cancerogenesis in colorectal cancer via AMPK-alpha-2-dependent inhibition of FTO and blocking FTO-mediated m6A modification of Myc proto-oncogene protein (MYC).
Responsed Disease	Colorectal cancer [ICD-11: 2B91]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation
Cell Process	Cell apoptosis
In-vitro Model	HCT 8	Colon adenocarcinoma	Homo sapiens	CVCL_2478
	SW480	Colon adenocarcinoma	Homo sapiens	CVCL_0546
	SW620	Colon adenocarcinoma	Homo sapiens	CVCL_0547
In-vivo Model	RC cells SW480 at logarithmic growth phase were prepared into cell suspension with a concentration of about 1 × 10⁷/100 L, which was then injected into the left axilla of nude mice with a 1 ml syringe to establish a subcutaneous mouse xenograft model. Once the tumor volume reached about 50 mm³, the nude mice were injected with miR-96 antagomir or NC antagomir (10 nmol once every 5 days for 5 weeks). After 5 weeks, the mice were euthanized, after which the subcutaneous transplanted tumor was removed, and weighed.
Experiment 2 Reporting the m6A-centered Disease Response				[17]
Response Summary	GSK3beta inhibited MZF1 expression by mediating FTO-regulated m6A modification of MZF1 and then decreased the proto-oncogene Myc proto-oncogene protein (MYC) expression, thus hampering CRC cell proliferation.
Responsed Disease	Colorectal cancer [ICD-11: 2B91]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Ubiquitin mediated proteolysis			hsa04120
Cell Process	Cell proliferation
In-vitro Model	SW620	Colon adenocarcinoma	Homo sapiens	CVCL_0547
	SW480	Colon adenocarcinoma	Homo sapiens	CVCL_0546
	HCT 8	Colon adenocarcinoma	Homo sapiens	CVCL_2478
In-vivo Model	Twenty-four specific pathogen free female BALB/c nude mice (age: 6 weeks, weight: 15 ~ 18 g) were purchased from Slac Laboratory Animal Co., Ltd., and subcutaneously injected with SW620 cells stably transfected with oe-NC, oe-GSK3-Beta + oe-NC, or oe-GSK3-Beta + oe-c-Myc to establish a subcutaneous xenograft tumour model in nude mice.
Experiment 3 Reporting the m6A-centered Disease Response				[27]
Response Summary	LINRIS blocked K139 ubiquitination of IGF2BP2, maintaining its stability. This process prevented the degradation of IGF2BP2 through the autophagy-lysosome pathway (ALP). The LINRIS-IGF2BP2-Myc proto-oncogene protein (MYC) axis promotes the progression of Colorectal cancer and is a promising therapeutic target. MYC-mediated glycolysis was influenced by the interaction between LINRIS and IGF2BP2.
Responsed Disease	Colorectal cancer [ICD-11: 2B91]
Target Regulator	Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	Ubiquitin mediated proteolysis			hsa04120
Pathway Response	Glycolysis / Gluconeogenesis			hsa00010
Cell Process	Autophagy-lysosome pathway
	Ubiquitination
	Glycolysis
In-vitro Model	DLD-1	Colon adenocarcinoma	Homo sapiens	CVCL_0248
In-vitro Model	HCT 116	Colon carcinoma	Homo sapiens	CVCL_0291
In-vivo Model	For the orthotopic models, 2 × 10⁶ cells with negative control (NC, sh-NC), sh-1 or sh-2 in 0.5 mL of PBS were subcutaneously injected into the dorsal flank of 2 mice respectively. Then 15 mice were separated into 3 groups (sh-NC, sh-1 and sh-2), of which the tumor pieces were tied to the base of the ceca. The growth of the tumors was monitored every 2 weeks after intraperitoneal injection of D-luciferin with a Xenogen IVIS 100 Bioluminescent Imaging System.
Experiment 4 Reporting the m6A-centered Disease Response				[6]
Response Summary	METTL3 exerted its function through enhancing Myc proto-oncogene protein (MYC) expression, at least partially in an m6A-IGF2BP1-dependent manner. Knockdown of METTL3 suppressed colorectal cancer cell proliferation in vitro and in vivo.
Responsed Disease	Colorectal cancer [ICD-11: 2B91]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation
In-vitro Model	HEK293T	Normal	Homo sapiens	CVCL_0063
	Caco-2	Colon adenocarcinoma	Homo sapiens	CVCL_0025
	HCT 116	Colon carcinoma	Homo sapiens	CVCL_0291
	HT29	Colon cancer	Mus musculus	CVCL_A8EZ
	LoVo	Colon adenocarcinoma	Homo sapiens	CVCL_0399
	SW480	Colon adenocarcinoma	Homo sapiens	CVCL_0546
	SW620	Colon adenocarcinoma	Homo sapiens	CVCL_0547
In-vivo Model	METTL3 stable knockdown or overexpression HCT116 cells were collected and resuspended at a density of 5 × 10⁶ or 3 × 10⁶ cells per 150 uL PBS.

Pancreatic cancer [ICD-11: 2C10]

Disease Info

In total 3 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[18]
Response Summary	FTO has been indicated to interact with Myc proto-oncogene protein (MYC) proto-oncogene, bHLH transcription factor and to enhance its stability by decreasing its m6A level.the aforementioned observations indicate a novel mechanism for the regulation of pancreatic cancer cells by FTO
Responsed Disease	Pancreatic cancer [ICD-11: 2C10]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation
In-vitro Model	BxPC-3	Pancreatic ductal adenocarcinoma	Homo sapiens	CVCL_0186
	HPDE	Normal	Homo sapiens	CVCL_4376
	PANC-1	Pancreatic ductal adenocarcinoma	Homo sapiens	CVCL_0480
	SW1990	Pancreatic adenocarcinoma	Homo sapiens	CVCL_1723
Experiment 2 Reporting the m6A-centered Disease Response				[28]
Response Summary	LncRNA-PACERR which bound to IGF2BP2 acts as an m6A-dependent manner to enhance the stability of KLF12 and Myc proto-oncogene protein (MYC) in cytoplasm. This study found that LncRNA-PACERR functions as key regulator of TAMs in PDAC microenvironment and revealed the novel mechanisms in cytoplasm and in nucleus.
Responsed Disease	Pancreatic ductal adenocarcinoma [ICD-11: 2C10.0]
Target Regulator	Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	mRNA surveillance pathway			hsa03015
	RNA degradation			hsa03018
Cell Process	RNA stability
In-vitro Model	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	PATU-8988 (Human pancreatic adenocarcinoma cell)
	PANC-1	Pancreatic ductal adenocarcinoma	Homo sapiens	CVCL_0480
	HEK293T	Normal	Homo sapiens	CVCL_0063
	37 (Pancreatic cancer cell)
In-vivo Model	BALB/c nude mice which were co-injected with THP-1 cells and PATU-8988 cells subcutaneously.
Experiment 3 Reporting the m6A-centered Disease Response				[25]
Response Summary	The study revealed important roles for METTL5 in the development of pancreatic cancer and present the METTL5/Myc proto-oncogene protein (MYC) axis as a novel therapeutic strategy for treatment.
Responsed Disease	Pancreatic cancer [ICD-11: 2C10]
Target Regulator	Methyltransferase-like 5 (METTL5)		WRITER	Regulator Info
Cell Process	Cell proliferation
	Cell migration
	Cell invasion

Liver cancer [ICD-11: 2C12]

Disease Info

In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[]
Response Summary	m6A-related genes have a prognostic value in liver cancer, and the constructed riskscore can identify patients who are high risk and can enable individualized therapy. Gene set enrichment analysis showed that tumorigenic markers, including DNA repair, E2F targets, G2M checkpoint, and Myc proto-oncogene protein (MYC) targets V1, were enriched in Cluster2.
Responsed Disease	Liver cancer [ICD-11: 2C12]
Experiment 2 Reporting the m6A-centered Disease Response				[22]
Response Summary	In contrast to the mRNA-decay-promoting function of YTH domain-containing family protein 2, IGF2BPs promote the stability and storage of their target mRNAs (for example, MYC) in an m6A-dependent manner under normal and stress conditions and therefore affect gene expression output. Four representative high confidence targets, including Myc proto-oncogene protein (MYC), FSCN1, TK1, and MARCKSL1, exhibit strong binding with IGF2BPs around their m6A motifs in control cells. Knocking down of each individual IGF2BPs in Hela (cervical cancer) and HepG2 (liver cancer) cells significantly repressed MYC expression.
Responsed Disease	Hepatocellular carcinoma [ICD-11: 2C12.02]
Target Regulator	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)		READER	Regulator Info
Cell Process	RNA decay
In-vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027
	HEK293T	Normal	Homo sapiens	CVCL_0063
	HeLa	Endocervical adenocarcinoma	Homo sapiens	CVCL_0030
	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027

Lung cancer [ICD-11: 2C25]

Disease Info

In total 4 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[8]
Response Summary	This study revealed that m6A methylation is closely related to the poor prognosis of non-small cell lung cancer patients via interference with the TIME, which suggests that m6A plays a role in optimizing individualized immunotherapy management and improving prognosis. The expression levels of METTL3, FTO and YTHDF1 in non-small cell lung cancer were changed. Patients in Cluster 1 had lower immunoscores, higher programmed death-ligand 1 (PD-L1) expression, and shorter overall survival compared to patients in Cluster 2. The Myc proto-oncogene protein (MYC) targets, E2 transcription Factor (E2F) targets were significantly enriched.
Responsed Disease	Non-small-cell lung carcinoma [ICD-11: 2C25.Y]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Pathway Response	p53 signaling pathway			hsa04115
	Central carbon metabolism in cancer			hsa05230
	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Experiment 2 Reporting the m6A-centered Disease Response				[7]
Response Summary	LCAT3 upregulation is attributable to N6-methyladenosine (m6A) modification mediated by methyltransferase like 3 (METTL3), leading to LCAT3 stabilization. LCAT3 as a novel oncogenic lncRNA in the lung, and validated the LCAT3-FUBP1-Myc proto-oncogene protein (MYC) axis as a potential therapeutic target for lung adenocarcinomas.
Responsed Disease	Lung adenocarcinoma [ICD-11: 2C25.0]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
In-vitro Model	A-549	Lung adenocarcinoma	Homo sapiens	CVCL_0023
	Calu-1	Lung squamous cell carcinoma	Homo sapiens	CVCL_0608
	HEK293T	Normal	Homo sapiens	CVCL_0063
	HOP-62	Lung adenocarcinoma	Homo sapiens	CVCL_1285
In-vivo Model	For the in vivo tumorigenicity assay, female BALB/c nude mice (ages 4-5 weeks) were randomly divided into two groups (n = 6/group). Calu1 cells (4 × 10⁶) that had been stably transfected with sh-LCAT3 or scramble were implanted subcutaneously into the nude mice. Tumor growth was measured after one week, and tumor volumes were calculated with the following formula: Volume (cm³) = (length × width²)/2. After four weeks, the mice were euthanized, and the tumors were collected and weighed. For the in vivo tumor invasion assay, 1.2 × 10⁶ scramble or shLCAT3 cells were injected intravenously into the tail vein of nude mice (n = 6/group). 1.5 mg luciferin (Gold Biotech, St Louis, MO, USA) was administered once a week for 4 weeks, to monitor metastases using an IVIS@ Lumina II system (Caliper Life Sciences, Hopkinton, MA, USA).
Experiment 3 Reporting the m6A-centered Disease Response				[8]
Response Summary	This study revealed that m6A methylation is closely related to the poor prognosis of non-small cell lung cancer patients via interference with the TIME, which suggests that m6A plays a role in optimizing individualized immunotherapy management and improving prognosis. The expression levels of METTL3, FTO and YTHDF1 in non-small cell lung cancer were changed. Patients in Cluster 1 had lower immunoscores, higher programmed death-ligand 1 (PD-L1) expression, and shorter overall survival compared to patients in Cluster 2. The Myc proto-oncogene protein (MYC) targets, E2 transcription Factor (E2F) targets were significantly enriched.
Responsed Disease	Non-small-cell lung carcinoma [ICD-11: 2C25.Y]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Pathway Response	p53 signaling pathway			hsa04115
	Central carbon metabolism in cancer			hsa05230
	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Experiment 4 Reporting the m6A-centered Disease Response				[8]
Response Summary	This study revealed that m6A methylation is closely related to the poor prognosis of non-small cell lung cancer patients via interference with the TIME, which suggests that m6A plays a role in optimizing individualized immunotherapy management and improving prognosis. The expression levels of METTL3, FTO and YTHDF1 in non-small cell lung cancer were changed. Patients in Cluster 1 had lower immunoscores, higher programmed death-ligand 1 (PD-L1) expression, and shorter overall survival compared to patients in Cluster 2. The Myc proto-oncogene protein (MYC) targets, E2 transcription Factor (E2F) targets were significantly enriched.
Responsed Disease	Non-small-cell lung carcinoma [ICD-11: 2C25.Y]
Target Regulator	YTH domain-containing family protein 1 (YTHDF1)		READER	Regulator Info
Pathway Response	p53 signaling pathway			hsa04115
	Central carbon metabolism in cancer			hsa05230
	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235

Breast cancer [ICD-11: 2C60]

Disease Info

In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[23]
Response Summary	Hypoxia-induced lncRNA KB-1980E6.3 is involved in the self-renewal and stemness maintenance of breast cancer stem cells by recruiting IGF2BP1 to regulate Myc proto-oncogene protein (MYC) mRNA stability.
Responsed Disease	Breast cancer [ICD-11: 2C60]
Target Regulator	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)		READER	Regulator Info
Target Regulation	Up regulation
Pathway Response	Signaling pathways regulating pluripotency of stem cells			hsa04550
In-vitro Model	BT-474	Invasive breast carcinoma	Homo sapiens	CVCL_0179
	BT-549	Invasive breast carcinoma	Homo sapiens	CVCL_1092
	HEK293T	Normal	Homo sapiens	CVCL_0063
	Hs 578T	Invasive breast carcinoma	Homo sapiens	CVCL_0332
	MCF-7	Invasive breast carcinoma	Homo sapiens	CVCL_0031
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens	CVCL_0062
	MDA-MB-453	Breast adenocarcinoma	Homo sapiens	CVCL_0418
	MDA-MB-468	Breast adenocarcinoma	Homo sapiens	CVCL_0419
	T-47D	Invasive breast carcinoma	Homo sapiens	CVCL_0553
In-vivo Model	The enriched mammosphere cells derived from engineered BT549 and Hs578T with silenced lncRNA KB-1980E6.3 (shKB/vector), BT549, and Hs578T with lncRNA KB-1980E6.3 knockdown combined with ectopic c-Myc (shKB/c-Myc), BT549, and Hs578T with silenced IGF2BP1 (shIGF2BP1/vector), BT549, and Hs578T with knocked down IGF2BP1 combined with ectopic c-Myc (shIGF2BP1/c-Myc), and BT549, and Hs578T/shNC/vector control cells were used in Xenograft experiments. Three doses (1 × 10⁵, 1 × 10⁴ and 1 × 10³) of spheres derived from the engineered Hs578T and 1 × 10⁵ of spheres derived from the engineered BT549 were subcutaneously inoculated into 4- to 6-week-old female nude mice (n = 5 per group). Mice were then treated with either bevacizumab (10 mg/kg every 3 days) to form a hypoxic tumor microenvironment or vehicle PBS to form a non-hypoxic condition
Experiment 2 Reporting the m6A-centered Disease Response				[13]
Response Summary	LCAT3 upregulation is attributable to m6A modification mediated by METTL3, leading to LCAT3 stabilization. Treated cells with tamoxifen to induce MYC activity. Highlights the therapeutic potential of RBPs by uncovering a critical role for YTHDF2 in counteracting the global increase of mRNA synthesis in Myc proto-oncogene protein (MYC)-driven breast cancers.
Responsed Disease	Breast cancer [ICD-11: 2C60]
Target Regulator	YTH domain-containing family protein 2 (YTHDF2)		READER	Regulator Info
Responsed Drug	Tamoxifen		Approved	Drug Info
Pathway Response	MAPK signaling pathway			hsa04010
Cell Process	Epithelial-to-mesenchymal transition
Cell Process	Cell apoptosis
In-vitro Model	HEK293T	Normal	Homo sapiens	CVCL_0063
	MCF-7	Invasive breast carcinoma	Homo sapiens	CVCL_0031
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens	CVCL_0062
	MBA-MD-231 (Human breast cancer cell)
	MYC-ER HMEC (Human mammary epithelial cells expressing a MYC estrogen receptor fusion)
	SK-BR-3	Breast adenocarcinoma	Homo sapiens	CVCL_0033
In-vivo Model	To induce recombination at 8 weeks of age both CAG-CreERT;Ythdf2^fl/fl and Ythdf2^fl/fl littermates were injected with 75mg/kg body weight tamoxifen dissolved in corn oil daily for 5 days.

Cervical cancer [ICD-11: 2C77]

Disease Info

In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[19]
Response Summary	FTO interacts with transcripts of E2F1 and Myc proto-oncogene protein (MYC), inhibition of FTO significantly impairs the translation efficiency of E2F1 and Myc.FTO plays important oncogenic role in regulating cervical cancer cells' proliferation.
Responsed Disease	Cervical cancer [ICD-11: 2C77]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation and migration
In-vitro Model	HeLa	Endocervical adenocarcinoma	Homo sapiens	CVCL_0030
In-vitro Model	SiHa	Cervical squamous cell carcinoma	Homo sapiens	CVCL_0032
Experiment 2 Reporting the m6A-centered Disease Response				[22]
Response Summary	In contrast to the mRNA-decay-promoting function of YTH domain-containing family protein 2, IGF2BPs promote the stability and storage of their target mRNAs (for example, MYC) in an m6A-dependent manner under normal and stress conditions and therefore affect gene expression output. Four representative high confidence targets, including Myc proto-oncogene protein (MYC), FSCN1, TK1, and MARCKSL1, exhibit strong binding with IGF2BPs around their m6A motifs in control cells. Knocking down of each individual IGF2BPs in Hela (cervical cancer) and HepG2 (liver cancer) cells significantly repressed MYC expression.
Responsed Disease	Cervical cancer [ICD-11: 2C77]
Target Regulator	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)		READER	Regulator Info
Cell Process	RNA decay
In-vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027
	HEK293T	Normal	Homo sapiens	CVCL_0063
	HeLa	Endocervical adenocarcinoma	Homo sapiens	CVCL_0030
	Hep-G2	Hepatoblastoma	Homo sapiens	CVCL_0027

Prostate cancer [ICD-11: 2C82]

Disease Info

In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[9]
Response Summary	METTL3 enhanced Myc proto-oncogene protein (MYC) expression by increasing m6A levels of MYC mRNA transcript, leading to oncogenic functions in prostate cancer.
Responsed Disease	Prostate cancer [ICD-11: 2C82]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation
	Cell migration
	Cell invasion
In-vitro Model	LNCaP C4-2	Prostate carcinoma	Homo sapiens	CVCL_4782
	DU145	Prostate carcinoma	Homo sapiens	CVCL_0105
	LNCaP	Prostate carcinoma	Homo sapiens	CVCL_0395
	PC-3	Prostate carcinoma	Homo sapiens	CVCL_0035

Bladder cancer [ICD-11: 2C94]

Disease Info

In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response			[10]
Response Summary	AF4/FMR2 family member 4 (AFF4), two key regulators of NF-Kappa-B pathway (IKBKB and RELA) and Myc proto-oncogene protein (MYC) were further identified as direct targets of METTL3-mediated m6A modification.overexpression of METTL3 significantly promoted Bladder cancer cell growth and invasion.
Responsed Disease	Bladder cancer [ICD-11: 2C94]
Target Regulator	Methyltransferase-like 3 (METTL3)	WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Glucose metabolism

Polycystic kidney disease [ICD-11: GB81]

Disease Info

In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response				[11]
Response Summary	Mettl3 activates the cyst-promoting c-Myc and cAMP pathways through enhanced Myc proto-oncogene protein (MYC) and Avpr2 mRNA m6A modification and translation. Thus, Mettl3 promotes Autosomal dominant polycystic kidney disease and links methionine utilization to epitranscriptomic activation of proliferation and cyst growth.
Responsed Disease	Polycystic kidney disease [ICD-11: GB81]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
In-vitro Model	mIMCD-3	Normal	Mus musculus	CVCL_0429
In-vivo Model	The clone, with one wild-type Mettl3 allele and one L1L2_Bact_P cassette inserted allele, was injected into C57BL/6 blastocysts. Mettl3-targeted mouse line was established from a germline-transmitting chimera. The chimeric mouse was crossed to C57BL/6 Flp mice to excise the neomycin resistance system.

Daunorubicin [Approved]

Drug Info

In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response				[26]
Response Summary	WTAP made acute myeloid leukemia cells resistant to daunorubicin. In further investigations, m6A methylation level was downregulated when knocking down WTAP, and Myc proto-oncogene protein (MYC) was upregulated due to the decreased m6A methylation of MYC mRNA.
Target Regulator	Wilms tumor 1-associating protein (WTAP)		WRITER	Regulator Info
Target Regulation	Up regulation
Responsed Disease	Acute myeloid leukaemia		ICD-11: 2A60	Disease Info
Cell Process	Cell cycle
	Cell proliferation
	Cell apoptosis
In-vitro Model	K-562	Chronic myelogenous leukemia	Homo sapiens	CVCL_0004
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064

Tamoxifen [Approved]

Drug Info

In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response				[13]
Response Summary	LCAT3 upregulation is attributable to m6A modification mediated by METTL3, leading to LCAT3 stabilization. Treated cells with tamoxifen to induce MYC activity. Highlights the therapeutic potential of RBPs by uncovering a critical role for YTHDF2 in counteracting the global increase of mRNA synthesis in Myc proto-oncogene protein (MYC)-driven breast cancers.
Target Regulator	YTH domain-containing family protein 2 (YTHDF2)		READER	Regulator Info
Responsed Disease	Breast cancer		ICD-11: 2C60	Disease Info
Pathway Response	MAPK signaling pathway			hsa04010
Cell Process	Epithelial-to-mesenchymal transition
Cell Process	Cell apoptosis
In-vitro Model	HEK293T	Normal	Homo sapiens	CVCL_0063
	MCF-7	Invasive breast carcinoma	Homo sapiens	CVCL_0031
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens	CVCL_0062
	MBA-MD-231 (Human breast cancer cell)
	MYC-ER HMEC (Human mammary epithelial cells expressing a MYC estrogen receptor fusion)
	SK-BR-3	Breast adenocarcinoma	Homo sapiens	CVCL_0033
In-vivo Model	To induce recombination at 8 weeks of age both CAG-CreERT;Ythdf2^fl/fl and Ythdf2^fl/fl littermates were injected with 75mg/kg body weight tamoxifen dissolved in corn oil daily for 5 days.

Linsitinib [Phase 3]

Drug Info

In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response			[12]
Response Summary	The IGF1/IGF1R inhibitor, linsitinib for further investigation based upon the role of the IGF pathway member, IGFBP3, as a downstream effector of YTHDF2-Myc proto-oncogene protein (MYC) axis in GSCs. Inhibiting glioblastoma stem cells viability without affecting NSCs and impairing in vivo glioblastoma growth.
Target Regulator	YTH domain-containing family protein 2 (YTHDF2)	READER	Regulator Info
Target Regulation	Up regulation
Responsed Disease	Glioblastoma	ICD-11: 2A00.00	Disease Info
In-vitro Model	NSC11 (Pluripotent derived neural progenitor cell)
	NHA (Normal human astrocytes)
	HNP1 (A human neural progenitor cell)
	ENSA (A human embryonic stem derived neural progenitor cell)
In-vivo Model	Implanting 5000 human derived GSCs into the right cerebral cortex of NSG mice at a depth of 3.5 mm under a University of California, San Diego Institutional Animal Care and Use Committee (IACUC) approved protocol. Brains were harvested and fixed in 4% formaldehyde, cryopreserved in 30% sucrose, and then cryosectioned. Hematoxylin and eosin (H&E) staining was performed on sections for histological analysis. In parallel survival experiments, mice were observed until the development of neurological signs. For in vivo drug treatment studies, intracranial xenografts were generated by implanting 5000 patient-derived GSCs (387 and 4121) into the right cerebral cortex of NSG mice as described above. Mice recovered for 7 days were randomly assigned into drug vs. treatment group by a blinded investigator. Mice were then treated daily with either vehicle (25 mM Tartaric acid) or 50 mg/kg linsitinib by oral gavage.

R-2HG [Investigative]

Drug Info

In total 2 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response				[14]
Response Summary	This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/Myc proto-oncogene protein (MYC)/CEBPA signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling.
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Down regulation
Responsed Disease	Glioma		ICD-11: 2A00.0	Disease Info
Cell Process	Glutamine metabolism
Cell Process	Cell apoptosis
In-vitro Model	8-MG-BA	Glioblastoma	Homo sapiens	CVCL_1052
	A-172	Glioblastoma	Homo sapiens	CVCL_0131
	DK-MG	Glioblastoma	Homo sapiens	CVCL_1173
	GaMG	Glioblastoma	Homo sapiens	CVCL_1226
	HEL	Erythroleukemia	Homo sapiens	CVCL_0001
	Jurkat	T acute lymphoblastic leukemia	Homo sapiens	CVCL_0065
	KOCL-45	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3993
	KOCL-48	Childhood acute monocytic leukemia	Homo sapiens	CVCL_6867
	KOCL-50	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6866
	KOCL-51	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6865
	KOCL-69	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3995
	KOPN-1	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3937
	LN-18	Glioblastoma	Homo sapiens	CVCL_0392
	LN-229	Glioblastoma	Homo sapiens	CVCL_0393
	MA9.3 (MA9.3)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	MA9.6 (MLL-AF9)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	ME-1 [Human leukemia]	Adult acute myeloid leukemia	Homo sapiens	CVCL_2110
	ML-2	Adult acute myeloid leukemia	Homo sapiens	CVCL_1418
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	NB4	Acute promyelocytic leukemia	Homo sapiens	CVCL_0005
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	PL21	Familial adenomatous polyposis	Homo sapiens	CVCL_JM48
	T98G	Glioblastoma	Homo sapiens	CVCL_0556
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	U-87MG ATCC	Glioblastoma	Homo sapiens	CVCL_0022
	U-937	Adult acute monocytic leukemia	Homo sapiens	CVCL_0007
In-vivo Model	For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation.
Experiment 2 Reporting the m6A-centered Drug Response				[14]
Response Summary	This work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/Myc proto-oncogene protein (MYC)/CEBPA signaling.High levels of FTO sensitize leukemia cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor activity in glioma. High levels of FTO sensitize leukemic cells to R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be reversed by the inhibition of MYC signaling.
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Down regulation
Responsed Disease	Leukaemia		ICD-11: 2B33.4	Disease Info
Cell Process	Glutamine metabolism
Cell Process	Cell apoptosis
In-vitro Model	8-MG-BA	Glioblastoma	Homo sapiens	CVCL_1052
	A-172	Glioblastoma	Homo sapiens	CVCL_0131
	DK-MG	Glioblastoma	Homo sapiens	CVCL_1173
	GaMG	Glioblastoma	Homo sapiens	CVCL_1226
	HEL	Erythroleukemia	Homo sapiens	CVCL_0001
	Jurkat	T acute lymphoblastic leukemia	Homo sapiens	CVCL_0065
	KOCL-45	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3993
	KOCL-48	Childhood acute monocytic leukemia	Homo sapiens	CVCL_6867
	KOCL-50	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6866
	KOCL-51	B acute lymphoblastic leukemia	Homo sapiens	CVCL_6865
	KOCL-69	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3995
	KOPN-1	B acute lymphoblastic leukemia	Homo sapiens	CVCL_3937
	LN-18	Glioblastoma	Homo sapiens	CVCL_0392
	LN-229	Glioblastoma	Homo sapiens	CVCL_0393
	MA9.3 (MA9.3)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	MA9.6 (MLL-AF9)
	MA9.6ITD (MLL-AF9 plus FLT3-ITD)
	MA9.6RAS (MLL-AF9 plus NRasG12D)
	ME-1 [Human leukemia]	Adult acute myeloid leukemia	Homo sapiens	CVCL_2110
	ML-2	Adult acute myeloid leukemia	Homo sapiens	CVCL_1418
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0064
	NB4	Acute promyelocytic leukemia	Homo sapiens	CVCL_0005
	NOMO-1	Adult acute monocytic leukemia	Homo sapiens	CVCL_1609
	PL21	Familial adenomatous polyposis	Homo sapiens	CVCL_JM48
	T98G	Glioblastoma	Homo sapiens	CVCL_0556
	THP-1	Childhood acute monocytic leukemia	Homo sapiens	CVCL_0006
	U-87MG ATCC	Glioblastoma	Homo sapiens	CVCL_0022
	U-937	Adult acute monocytic leukemia	Homo sapiens	CVCL_0007
In-vivo Model	For R-2HG injection mouse models, sensitive (NOMO-1 and MA9.3ITD) or resistant (MA9.3RAS) cells were injected into NSGS or NRGS intravenously, and then R-2HG (6mg/kg body weight) or PBS were injected once daily through tail vein for 12 consecutive days starting from day 11 post xeno-transplantation.

References

Ref 1	The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017 Nov;23(11):1369-1376. doi: 10.1038/nm.4416. Epub 2017 Sep 18.
Ref 2	[Methyltransferase-like 3 Promotes the Proliferation of Acute Myeloid Leukemia Cells by Regulating N6-methyladenosine Levels of MYC]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Jun 28;40(3):308-314. doi: 10.3881/j.issn.1000-503X.2018.03.002.
Ref 3	METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m(6)A Modification. Mol Ther Nucleic Acids. 2020 Jun 5;20:1-12. doi: 10.1016/j.omtn.2020.01.033. Epub 2020 Feb 4.
Ref 4	METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway. Front Oncol. 2020 Feb 26;10:115. doi: 10.3389/fonc.2020.00115. eCollection 2020.
Ref 5	HBXIP promotes gastric cancer via METTL3-mediated MYC mRNA m6A modification. Aging (Albany NY). 2020 Oct 13;12(24):24967-24982. doi: 10.18632/aging.103767. Epub 2020 Oct 13.
Ref 6	N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression. Am J Transl Res. 2020 May 15;12(5):1789-1806. eCollection 2020.
Ref 7	LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC. J Hematol Oncol. 2021 Jul 17;14(1):112. doi: 10.1186/s13045-021-01123-0.
Ref 8	Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles. Ann Transl Med. 2021 Sep;9(18):1465. doi: 10.21037/atm-21-4248.
Ref 9	The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J Cancer. 2020 Mar 25;11(12):3588-3595. doi: 10.7150/jca.42338. eCollection 2020.
Ref 10	The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-KappaB/MYC signaling network. Oncogene. 2019 May;38(19):3667-3680. doi: 10.1038/s41388-019-0683-z. Epub 2019 Jan 18.
Ref 11	A methionine-Mettl3-N(6)-methyladenosine axis promotes polycystic kidney disease. Cell Metab. 2021 Jun 1;33(6):1234-1247.e7. doi: 10.1016/j.cmet.2021.03.024. Epub 2021 Apr 13.
Ref 12	The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2021 Feb;11(2):480-499. doi: 10.1158/2159-8290.CD-20-0331. Epub 2020 Oct 6.
Ref 13	Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell. 2021 Aug 5;81(15):3048-3064.e9. doi: 10.1016/j.molcel.2021.06.014. Epub 2021 Jul 2.
Ref 14	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Cell. 2018 Jan 11;172(1-2):90-105.e23. doi: 10.1016/j.cell.2017.11.031. Epub 2017 Dec 14.
Ref 15	WNT/Beta-catenin-suppressed FTO expression increases m(6)A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis. Cell Death Dis. 2021 May 8;12(5):462. doi: 10.1038/s41419-021-03739-z.
Ref 16	microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKAlpha2-FTO-m6A/MYC axis. J Exp Clin Cancer Res. 2020 Nov 12;39(1):240. doi: 10.1186/s13046-020-01731-7.
Ref 17	Kinase GSK3Beta functions as a suppressor in colorectal carcinoma through the FTO-mediated MZF1/c-Myc axis. J Cell Mol Med. 2021 Mar;25(5):2655-2665. doi: 10.1111/jcmm.16291. Epub 2021 Feb 2.
Ref 18	The role of the fat mass and obesity-associated protein in the proliferation of pancreatic cancer cells. Oncol Lett. 2019 Feb;17(2):2473-2478. doi: 10.3892/ol.2018.9873. Epub 2018 Dec 28.
Ref 19	The m(6)A eraser FTO facilitates proliferation and migration of human cervical cancer cells. Cancer Cell Int. 2019 Dec 2;19:321. doi: 10.1186/s12935-019-1045-1. eCollection 2019.
Ref 20	YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021 Jul 8;138(1):71-85. doi: 10.1182/blood.2020009676.
Ref 21	N(6)-methyladenosine (m(6)A) reader IGF2BP1 accelerates gastric cancer aerobic glycolysis in c-Myc-dependent manner. Exp Cell Res. 2022 Aug 1;417(1):113176. doi: 10.1016/j.yexcr.2022.113176. Epub 2022 Apr 27.
Ref 22	Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018 Mar;20(3):285-295. doi: 10.1038/s41556-018-0045-z. Epub 2018 Feb 23.
Ref 23	A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability. Oncogene. 2021 Mar;40(9):1609-1627. doi: 10.1038/s41388-020-01638-9. Epub 2021 Jan 19.
Ref 24	METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification. Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.
Ref 25	Ribosome 18S m(6)A methyltransferase METTL5 promotes pancreatic cancer progression by modulating c?Myc translation. Int J Oncol. 2022 Jan;60(1):9. doi: 10.3892/ijo.2021.5299. Epub 2021 Dec 31.
Ref 26	High Wilms' tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m(6)A methylation of MYC mRNA. J Cancer Res Clin Oncol. 2021 Jan;147(1):33-47. doi: 10.1007/s00432-020-03373-w. Epub 2020 Sep 3.
Ref 27	LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer. 2019 Dec 2;18(1):174. doi: 10.1186/s12943-019-1105-0.
Ref 28	LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2022 May 7;15(1):52. doi: 10.1186/s13045-022-01272-w.

m6A Target Gene Information

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map